<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1292" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1292/" /><meta name="ncbi_pagename" content="Fabry Disease - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Fabry Disease - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Fabry Disease" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/01/05" /><meta name="citation_author" content="Atul Mehta" /><meta name="citation_author" content="Derralynn A Hughes" /><meta name="citation_pmid" content="20301469" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1292/" /><meta name="citation_keywords" content="Alpha-Galactosidase A Deficiency" /><meta name="citation_keywords" content="Anderson-Fabry Disease" /><meta name="citation_keywords" content="Alpha-Galactosidase A Deficiency" /><meta name="citation_keywords" content="Anderson-Fabry Disease" /><meta name="citation_keywords" content="Classic Fabry Disease" /><meta name="citation_keywords" content="Atypical and Late-Onset Variants of Fabry Disease" /><meta name="citation_keywords" content="Alpha-galactosidase A" /><meta name="citation_keywords" content="GLA" /><meta name="citation_keywords" content="Fabry Disease" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Fabry Disease" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Atul Mehta" /><meta name="DC.Contributor" content="Derralynn A Hughes" /><meta name="DC.Date" content="2017/01/05" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1292/" /><meta name="description" content="Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (α-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% α-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype." /><meta name="og:title" content="Fabry Disease" /><meta name="og:type" content="book" /><meta name="og:description" content="Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (α-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% α-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1292/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/fabry/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1292/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8AA828E04214110000000003A60178.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1292_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1292_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/xl-nystag/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fsh/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1292_"><span class="title" itemprop="name">Fabry Disease</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Alpha-Galactosidase A Deficiency, Anderson-Fabry Disease</div><p class="contrib-group"><span itemprop="author">Atul Mehta</span>, MA, MD, FRCP, FRCPath and <span itemprop="author">Derralynn A Hughes</span>, MA, DPhil, FRCP, FRCPath.</p><a data-jig="ncbitoggler" href="#__NBK1292_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1292_ai__"><div class="contrib half_rhythm"><span itemprop="author">Atul Mehta</span>, MA, MD, FRCP, FRCPath<div class="affiliation small">Director, Lysosomal Storage Disorders Unit<br />Consultant Haematologist, Royal Free Hospital<br />University College London School of Medicine<br />London, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ten.shn@1athem.luta" class="oemail">ten.shn@1athem.luta</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Derralynn A Hughes</span>, MA, DPhil, FRCP, FRCPath<div class="affiliation small">Senior Lecturer Haematology, Lysosomal Storage Disorders Unit<br />Department of Haematology<br />Royal Free Hospital<br />University College London<br />London, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.lcu@hadvgmr" class="oemail">ku.ca.lcu@hadvgmr</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">August 5, 2002</span>; Last Update: <span itemprop="dateModified">January 5, 2017</span>.</p><p><em>Estimated reading time: 39 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="fabry.Summary" itemprop="description"><h2 id="_fabry_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (&#x003b1;-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% &#x003b1;-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>In contrast, males with greater than 1% &#x003b1;-Gal A activity may have: (1) a cardiac variant <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Identification of deficient &#x003b1;-Gal A enzyme activity in plasma, <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> leukocytes, and/or cultured cells is the most efficient and reliable method of diagnosing Fabry disease in males. Identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> confirms the diagnosis in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>. Identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>GLA</i> pathogenic variant by molecular genetic testing confirms the diagnosis in a heterozygous female.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: Diphenylhydantoin, carbamazepine, or gabapentin to reduce pain (acroparesthesia); ACE inhibitors or angiotensin receptor blockers to reduce proteinuria; chronic hemodialysis and/or renal transplantation for ESRD.</p><p><i>Prevention of primary complications:</i> The role of enzyme replacement therapy (ERT) in the long-term prophylaxis of renal, cardiac, and CNS manifestations is unproven; however, experts recommend that ERT be initiated as early as possible in all males with Fabry disease (including children and those with ESRD undergoing dialysis and renal transplantation) and in females with significant disease because all are at high risk for cardiac, cerebrovascular, and renal complications.</p><p><i>Prevention of secondary complications</i>: Prophylaxis for renovascular disease, ischemic heart disease, and cerebrovascular disease as for the general population.</p><p><i>Surveillance</i>: Annual or more frequent assessment of renal function; annual cardiology and audiology evaluations; biennial brain MRI/MRA.</p><p><i>Agents/circumstances to avoid</i>: Smoking.</p><p><i>Evaluation of relatives at risk</i>: Early identification of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> relatives by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known in order to initiate ERT as early as possible in affected individuals.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Fabry disease is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>). If only one male in a family is affected, his mother is likely <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>; rarely, a single affected male in a family may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. A heterozygous female has a 50% chance of transmitting the <i>GLA</i> pathogenic variant in each pregnancy. An affected male transmits his pathogenic variant to all of his daughters. Heterozygote (carrier) testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variant in a family is known.</p></div></div><div id="fabry.GeneReview_Scope"><h2 id="_fabry_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="fabry.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1292/table/fabry.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fabry.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_fabry.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fabry Disease: Included Phenotypes</th></tr></thead><tbody><tr><td headers="hd_h_fabry.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Classic Fabry disease</div></li><li class="half_rhythm"><div>Atypical and late-onset variants of Fabry disease</div></li></ul>
</td></tr></tbody></table></div></div></div><div id="fabry.Diagnosis"><h2 id="_fabry_Diagnosis_">Diagnosis</h2><div id="fabry.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Fabry disease <b>should be suspected</b> in males and females with the following clinical features:</p><ul><li class="half_rhythm"><div>Periodic crises of severe pain in the extremities (acroparesthesia)</div></li><li class="half_rhythm"><div>Vascular cutaneous lesions (angiokeratomas)</div></li><li class="half_rhythm"><div>Sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis)</div></li><li class="half_rhythm"><div>Characteristic corneal and lenticular opacities</div></li><li class="half_rhythm"><div>Unexplained stroke</div></li><li class="half_rhythm"><div>Unexplained left ventricular hypertrophy</div></li><li class="half_rhythm"><div>Renal insufficiency of unknown etiology including unexplained proteinuria or microalbuminuria</div></li></ul></div><div id="fabry.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>A diagnostic algorithm is provided in <a class="bk_pop" href="#fabry.REF.gal.2011">Gal et al [2011]</a> (see <a href="/pmc/articles/PMC3063537/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>) and an approach to investigations of variants of <a class="def" href="/books/n/gene/glossary/def-item/unknown-significance/">unknown significance</a> described in <a class="bk_pop" href="#fabry.REF.smid.2014.400">Smid et al [2014]</a>.</p><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of Fabry disease <b>is established</b> in a male proband by:</p><ul><li class="half_rhythm"><div class="half_rhythm">Identification of deficient alpha-galactosidase A (&#x003b1;-Gal A) enzyme activity in plasma, <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> leukocytes, and/or cultured cells. The test is a fluorometric assay and uses the substrate 4-methylumbelliferyl-&#x003b1;-D-galactopyranoside.</div><ul><li class="half_rhythm"><div>Males with classic Fabry disease have &#x0003c;1% &#x003b1;-Gal A enzyme activity.</div></li><li class="half_rhythm"><div>Males with atypical Fabry disease have residual enzyme activity &#x0003e;1% of normal.</div></li></ul><div class="half_rhythm">Note: Both plasma and leukocyte enzyme activity should be assayed, as some pathogenic variants (e.g., <a class="figpopup" href="/books/NBK1292/table/fabry.T.selected_gla_variants/?report=objectonly" target="object" rid-figpopup="figfabryTselectedglavariants" rid-ob="figobfabryTselectedglavariants">p.Asn215Ser</a>) affect intracellular trafficking or packaging/secretion of the enzyme, such that the reduction in enzyme activity in plasma is more marked than the reduction in enzyme activity in leukocytes.</div></li><li class="half_rhythm"><div class="half_rhythm">Identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>GLA</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1292/table/fabry.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="figfabryTmoleculargenetictestingusedi" rid-ob="figobfabryTmoleculargenetictestingusedi">Table 1</a>).</div></li></ul><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of Fabry disease <b>is established</b> in a female proband by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>GLA</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1292/table/fabry.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="figfabryTmoleculargenetictestingusedi" rid-ob="figobfabryTmoleculargenetictestingusedi">Table 1</a>).</p><p>Note: Measurement of &#x003b1;-Gal A enzyme activity is unreliable for identification of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females. Although demonstration of markedly decreased &#x003b1;-Gal A enzyme activity in a female is diagnostic of the heterozygous state, some heterozygotes have &#x003b1;-Gal A activity in the normal range.</p><div id="fabry.Molecular_Testing"><h4>Molecular Testing</h4><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>GLA</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div><div class="half_rhythm">Targeted analysis for the p.Ala143Pro <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can be performed first in individuals from Nova Scotia (incidence 1:15,000).</div><div class="half_rhythm">Targeted analysis for the IVS4+919G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can be performed first in individuals of Chinese ancestry with atypical presentation (see <a href="#fabry.Molecular_Genetics">Molecular Genetics</a>) [Liu et al].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>GLA</i> and other genes of interest (see <a href="#fabry.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> may be considered if single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) has not confirmed a diagnosis in an individual with features of Fabry disease. Such testing may include <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>, and mitochondrial sequencing.</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="fabry.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Fabry Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1292/table/fabry.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fabry.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>GLA</i></td><td headers="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~95%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5,&#x000a0;6</sup></td><td headers="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~5%&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="fabry.TF.1.1"><p class="no_margin">See <a href="/books/NBK1292/#fabry.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="fabry.TF.1.2"><p class="no_margin">See <a href="#fabry.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="fabry.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="fabry.TF.1.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a></p></div></dd><dt>5. </dt><dd><div id="fabry.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="fabry.TF.1.6"><p class="no_margin">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis can be used (a) to confirm a putative <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>/whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in males after failure to amplify by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> in <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and (b) to identify partial- and whole-gene deletions in females.</p></div></dd><dt>7. </dt><dd><div id="fabry.TF.1.7"><p class="no_margin"><a class="bk_pop" href="#fabry.REF.bernstein.1989.1390">Bernstein et al [1989]</a>, <a class="bk_pop" href="#fabry.REF.kornreich.1990.9319">Kornreich et al [1990]</a></p></div></dd></dl></div></div></div></div><div id="fabry.Additional_Testing"><h4>Additional Testing</h4><p><b>Biomarkers</b></p><ul><li class="half_rhythm"><div>Plasma globotriaosylsphingosine (lyso-Gb3) (the lyso derivative of the accumulated substrate) levels appear to correlate with disease severity and to decline with enzyme replacement therapy [<a class="bk_pop" href="#fabry.REF.aerts.2008.2812">Aerts et al 2008</a>].</div></li><li class="half_rhythm"><div>Urinary levels of lyso-Gb3 derivatives also correlate with disease severity [<a class="bk_pop" href="#fabry.REF.aurayblais.2015.195">Auray-Blais et al 2015</a>].</div></li><li class="half_rhythm"><div>Plasma lyso-Gb3 levels are higher in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males than females.</div></li><li class="half_rhythm"><div>Identification of elevated plasma and urinary lyso-Gb3 can confirm the diagnosis in an individual with a <i>GLA</i> variant of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> or late-onset disease manifestations. <a class="bk_pop" href="#fabry.REF.niemann.2014.8">Niemann et al [2014]</a> reported that individuals with a novel variant and organ involvement consistent with Fabry disease had lyso-Gb3 levels &#x02265;2.7ng/mL; Individuals with a novel <i>GLA</i> variant and no organ involvement had lyso-Gb3 levels &#x0003c;2.7 ng/mL.</div></li></ul><p>Note: There are no universally recognized biomarkers of Fabry disease.</p><p><b>Endomyocardial biopsy.</b> Identification of characteristic globotriaosylceramide (GL-3) inclusions on endomyocardial biopsy can establish a diagnosis in an individual with left ventricular hypertrophy and a <i>GLA</i> variant of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> [<a class="bk_pop" href="#fabry.REF.hsu.2014.96">Hsu et al 2014</a>].</p></div></div></div><div id="fabry.Clinical_Characteristics"><h2 id="_fabry_Clinical_Characteristics_">Clinical Characteristics</h2><div id="fabry.Clinical_Description"><h3>Clinical Description</h3><p>Fabry disease encompasses a spectrum of phenotypes ranging from the severe classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> to atypical forms. The classic phenotype is probably the most common, although atypical forms of the disease, which present later in life, may be underdiagnosed [<a class="bk_pop" href="#fabry.REF.sachdev.2002.1407">Sachdev et al 2002</a>, <a class="bk_pop" href="#fabry.REF.nakao.2003.801">Nakao et al 2003</a>].</p><p>The Fabry Outcome Survey (FOS) and the Fabry Registry, multicenter international initiatives designed to examine the natural history of Fabry disease and the effects of enzyme replacement therapy, are an important source of new data on the disease [<a class="bk_pop" href="#fabry.REF.mehta.2004.236">Mehta et al 2004</a>, <a class="bk_pop" href="#fabry.REF.eng.2007.184">Eng et al 2007</a>].</p><div id="fabry.T.major_manifestations_in_classic" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Major Manifestations in Classic and Atypical Fabry Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1292/table/fabry.T.major_manifestations_in_classic/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fabry.T.major_manifestations_in_classic_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic</th><th id="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Renal Variant</th><th id="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardiac Variant</th></tr></thead><tbody><tr><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Age at onset</b></td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4-8 yrs</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;25 yrs</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;40 yrs</td></tr><tr><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Average age of death</b></td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">41 yrs</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;60 yrs</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;60 yrs</td></tr><tr><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" rowspan="8" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Manifestation</b></td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Angiokeratoma</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">++</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td></tr><tr><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Acroparesthesia</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">++</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;/+</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td></tr><tr><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hypohidrosis/anhidrosis</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">++</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;/+</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td></tr><tr><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Corneal/lenticular opacity</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td></tr><tr><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Cardiac disease</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LVH/ischemia</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LVH</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LVH/cardiomyopathy</td></tr><tr><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Cerebrovascular disease</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">TIA/stroke</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td></tr><tr><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Renal disease</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ESRD</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ESRD</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proteinuria</td></tr><tr><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Residual &#x003b1;-Gal A enzyme activity</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;1%</td><td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;1%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#fabry.REF.mehta.2004.236">Mehta et al [2004]</a>, <a class="bk_pop" href="#fabry.REF.eng.2007.184">Eng et al [2007]</a></p></div></dd><dt>+ </dt><dd><div id="fabry.TF.2.1"><p class="no_margin">= present; &#x02013; = absent; &#x003b1;-Gal A = alpha-galactosidase A; ESRD = end-stage renal disease; LVH = left ventricular hypertrophy; TIA = transient ischemic attack</p></div></dd></dl></div></div></div><div id="fabry.Classic_Fabry_Disease"><h4>Classic Fabry Disease</h4><p>Onset of symptoms usually occurs in childhood or adolescence with the appearance of angiokeratomas, periodic crises of severe pain in the extremities (acroparesthesia), hypohidrosis, and the characteristic corneal and lenticular opacities. Although proteinuria may be detected early, renal insufficiency usually occurs in the third to fifth decade of life. Death occurs from complications of renal disease, cardiac involvement, and/or cerebrovascular disease.</p><p><b>Angiokeratomas</b> are often one of the earliest manifestations of Fabry disease. They appear as clusters of punctate, dark red to blue-black angiectases in the superficial layers of the skin. The lesions may be flat or slightly raised and do not blanch with pressure. Slight hyperkeratosis is notable in larger lesions.</p><p>The clusters of lesions are most dense between the umbilicus and the knees; they most commonly involve the hips, back, thighs, buttocks, penis, and scrotum, and tend to be bilaterally symmetric. The oral mucosa, conjunctiva, and other mucosal areas are commonly involved. A wide variation in the distribution pattern and density of the lesions may occur. Examination of the skin, especially the scrotum and umbilicus, may reveal the presence of <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> lesions. Data from 714 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals (345 males, 369 females) in the FOS [<a class="bk_pop" href="#fabry.REF.orteu.2007.331">Orteu et al 2007</a>] suggest that they are present in 66% of males (36% of females).</p><p>The number and size of these cutaneous vascular lesions progressively increase with age. The presence of angiokeratoma correlated with the severity of the systemic disease manifestations [<a class="bk_pop" href="#fabry.REF.zampetti.2012.712">Zampetti et al 2012</a>].</p><p><b>Acroparesthesia</b> occurs as episodic crises of agonizing, burning pain in the distal extremities that most often begin in childhood or early adolescence and signal clinical onset of the disease. These crises last from minutes to several days and are usually triggered by exercise, fatigue, emotional stress, or rapid changes in temperature and humidity. Often the pain radiates to the proximal extremities and other parts of the body. Attacks of abdominal or flank pain may simulate appendicitis or renal colic.</p><p>The crises usually decrease in frequency and severity with increasing age; however, in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, the frequency increases and the pain can be so excruciating and incapacitating that the individual may contemplate suicide.</p><p><b>Hypohidrosis or anhidrosis</b> is an early and almost constant finding. Hyperhidrosis also occurs; in the FOS it was seen in 12% of females and 6.4% of males [<a class="bk_pop" href="#fabry.REF.lidove.2006.1053">Lidove et al 2006</a>].</p><p><b>Cornea verticillata,</b> the characteristic corneal opacity that is observed only by slit-lamp microscopy, is found in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males and most <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females. The earliest corneal lesion is a diffuse haziness in the subepithelial layer. With time, the opacities appear as whorled streaks extending from a central vortex to the periphery of the cornea. The whorl-like opacities, typically inferior and cream colored, range from white to golden brown and may be very faint [<a class="bk_pop" href="#fabry.REF.nguyen.2005.164">Nguyen et al 2005</a>]. In the FOS, cornea verticillata was present in 77% of females and 73% of males undergoing detailed ophthalmologic examination [<a class="bk_pop" href="#fabry.REF.sodi.2007.210">Sodi et al 2007</a>].</p><p><b>Lenticular changes</b> are present in approximately 30% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males and include a granular anterior capsular or subcapsular deposit and a unique, possibly pathognomonic, lenticular opacity (the "Fabry cataract"). The cataracts, which are best observed through a dilated pupil by slit-lamp examination using retroillumination, are whitish, spoke-like deposits of fine granular material on or near the posterior lens capsule. These lines usually radiate from the central part of the posterior cortex. The corneal and lenticular opacities do not interfere with visual acuity.</p><p><b>Other ocular features.</b> Aneurysmal dilatation and tortuosity of conjunctival and retinal vessels also occur; while not specific for Fabry disease, vessel tortuosity is observed more frequently in individuals with a higher disease severity score [<a class="bk_pop" href="#fabry.REF.sodi.2007.210">Sodi et al 2007</a>, <a class="bk_pop" href="#fabry.REF.allen.2010.1602">Allen et al 2010</a>]. Data from the FOS demonstrates that the ocular changes correlate well with overall disease severity and with <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> [<a class="bk_pop" href="#fabry.REF.pitz.2015.e0120814">Pitz et al 2015</a>].</p><p><b>Cardiac disease.</b> Mitral insufficiency may be present in childhood or adolescence. Left ventricular enlargement and conduction abnormalities are early findings. Left ventricular hypertrophy, often associated with hypertrophy of the interventricular septum and appearing similar to hypertrophic cardiomyopathy (HCM), is progressive and occurs earlier in males than females [<a class="bk_pop" href="#fabry.REF.kampmann.2005.15">Kampmann et al 2005</a>]. Cardiac disease is present in most males with the classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> by middle age and is the major cause of morbidity and mortality in those who have undergone dialysis or transplantation for treatment of end-stage renal disease (ESRD).</p><p>ECG changes including ST segment changes, T-wave inversion, and dysrhythmias such as a short PR interval and intermittent supraventricular tachycardias may be caused by infiltration of the conduction system. Echocardiography demonstrates an increased thickness of the interventricular septum and the left ventricular posterior wall [<a class="bk_pop" href="#fabry.REF.pieroni.2006.1663">Pieroni et al 2006</a>]. Magnetic resonance studies using gadolinium demonstrated late enhancement areas, corresponding to myocardial fibrosis and associated with decreased regional functioning as assessed by strain and strain-rate imaging [<a class="bk_pop" href="#fabry.REF.moon.2003.2151">Moon et al 2003</a>, <a class="bk_pop" href="#fabry.REF.weidemann.2005.1221">Weidemann et al 2005</a>]. T<sub>1</sub> mapping illustrates intramural fat deposition and posterior wall fibrosis [<a class="bk_pop" href="#fabry.REF.sado.2013.392">Sado et al 2013</a>].</p><p>Among 714 predominantly adult individuals in the FOS [<a class="bk_pop" href="#fabry.REF.linhart.2007.1228">Linhart et al 2007</a>], angina, palpitations/arrhythmia, and exertional dyspnea were found in 23%-27% of males and 22%-25% of females. Hypertension, angina pectoris, myocardial ischemia and infarction, congestive heart failure, and severe mitral regurgitation are late signs. Hypertension was found in more than 50% of males and more than 40% of females in the FOS [<a class="bk_pop" href="#fabry.REF.kleinert.2006.782">Kleinert et al 2006</a>].</p><p><b>Cerebrovascular manifestations</b> result primarily from multifocal small vessel involvement and may include thrombosis, transient ischemic attacks (TIA), basilar artery ischemia and aneurysm, seizures, hemiplegia, hemianesthesia, aphasia, labyrinthine disorders, or frank cerebral hemorrhage [<a class="bk_pop" href="#fabry.REF.politei.2006.103">Politei &#x00026; Capizzano 2006</a>]. FOS data indicate that stroke or TIA occur in approximately 13% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals overall (15% males, 11.5% females) [<a class="bk_pop" href="#fabry.REF.ginsberg.2006.57">Ginsberg et al 2006</a>]. The Fabry Registry has reported that cerebrovascular manifestations are often a presenting feature of Fabry disease and may be more frequent than previously recognized [<a class="bk_pop" href="#fabry.REF.sims.2009.788">Sims et al 2009</a>]. <a class="bk_pop" href="#fabry.REF.rolfs.2005.1794">Rolfs et al [2005]</a> reported that in Germany a <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was identified in 21 of 432 males (4.9%) and seven of 289 females (2.4%) age 18-55 years suffering cryptogenic stroke. However, other studies have not confirmed such a high prevalence [<a class="bk_pop" href="#fabry.REF.brouns.2010.863">Brouns et al 2010</a>, <a class="bk_pop" href="#fabry.REF.wozniak.2010.78">Wozniak et al 2010</a>, <a class="bk_pop" href="#fabry.REF.rolfs.2013.340">Rolfs et al 2013</a>]. Thromboembolic events are more common among individuals with Fabry disease who also have the factor V Leiden variant [<a class="bk_pop" href="#fabry.REF.lenders.2015.1009">Lenders et al 2015</a>].</p><p>In addition, a distinct neurologic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> including decreased motor performance and nonmotor neurologic manifestations has been described. Individuals with Fabry disease showed slower gait and transfer speed, poorer fine manual dexterity, and slower hand speed than controls. Affected individuals had an increased incidence of depression, pain, and daytime sleepiness but did not exhibit extrapyramidal motor features or signs of significant cognitive impairment [<a class="bk_pop" href="#fabry.REF.l_hle.2015.1454">L&#x000f6;hle et al 2015</a>].</p><p><b>Renal involvement.</b> Progressive glycosphingolipid accumulation in the kidney interferes with renal function, resulting in azotemia and renal insufficiency.</p><p>During childhood and adolescence, protein, casts, red cells, and birefringent lipid globules with characteristic "Maltese crosses" can be observed in the urinary sediment. Proteinuria, isosthenuria, and a gradual deterioration of tubular reabsorption, secretion, and excretion occur with advancing age. Polyuria and a syndrome similar to vasopressin-resistant diabetes insipidus occasionally develop.</p><p>Gradual deterioration of renal function and the development of azotemia usually occur in the third to fifth decade of life, although ESRD has been reported in the second decade. Death most often results from ESRD unless chronic hemodialysis or renal transplantation is undertaken. The mean age at death of males not treated for ESRD is 41 years, but occasionally an untreated male with the classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> survives into the seventh decade.</p><p><b>Other clinical features.</b> In addition to the major clinical features described above, males and females with the classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may have gastrointestinal, auditory, pulmonary, and other manifestations.</p><ul><li class="half_rhythm"><div><b>Gastrointestinal.</b> Glycosphingolipid deposition in intestinal small vessels and in the autonomic ganglia of the bowel may cause episodic diarrhea, nausea, vomiting, bloating, cramping abdominal pain, and/or intestinal malabsorption [<a class="bk_pop" href="#fabry.REF.hoffmann.2007.1447">Hoffmann et al 2007</a>]. Achalasia and jejunal diverticulosis, which may lead to perforation of the small bowel, have been described. Radiographic studies may reveal thickened, edematous colonic folds, mild dilatation of the small bowel, a granular-appearing ileum, and the loss of haustral markings throughout the colon.</div></li><li class="half_rhythm"><div><b>Pulmonary.</b> Several <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have had pulmonary involvement, manifest clinically as chronic bronchitis, wheezing, or dyspnea. Primary pulmonary involvement has been reported in the absence of cardiac or renal disease. Pulmonary function studies may show an obstructive component [<a class="bk_pop" href="#fabry.REF.magage.2007.790">Magage et al 2007</a>] which has been demonstrated to stabilize with enzyme replacement therapy (ERT) [<a class="bk_pop" href="#fabry.REF.odler.2017.942">Odler et al 2017</a>].</div></li><li class="half_rhythm"><div><b>Vascular.</b> Pitting edema of the lower extremities may be present in adulthood in the absence of hypoproteinemia, varices, or other clinically significant vascular disease. Although the pitting edema is initially reversible, progressive glycosphingolipid deposition in the lymphatic vessels and lymph nodes results in irreversible lymphedema requiring treatment with compression hosiery. Varicosities, hemorrhoids, and priapism have also been reported.</div></li><li class="half_rhythm"><div><b>Cranial nerve VIII involvement.</b> High-frequency hearing loss, tinnitus, and dizziness have been reported [<a class="bk_pop" href="#fabry.REF.hegemann.2006.654">Hegemann et al 2006</a>].</div></li><li class="half_rhythm"><div><b>Psychological.</b> Depression, anxiety, severe fatigue, and other psychosocial manifestations lead to decreased quality of life in many <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#fabry.REF.cole.2007.943">Cole et al 2007</a>].</div></li></ul></div><div id="fabry.Heterozygous_Carrier_Females"><h4>Heterozygous (Carrier) Females</h4><p>The clinical manifestations in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females range from asymptomatic throughout a normal life span to as severe as <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males. Variation in clinical manifestations is attributed to random <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> [<a class="bk_pop" href="#fabry.REF.deegan.2006.347">Deegan et al 2006</a>]. More severely affected females are more likely to express the X chromosome with the <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in affected organs [<a class="bk_pop" href="#fabry.REF.echevarria.2016.44">Echevarria et al 2016</a>].</p><p>Most <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females from families in which <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males have the classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have a milder clinical course and better prognosis than affected males.</p><p>Mild manifestations include the characteristic cornea verticillata (70%-90%) and lenticular opacities that do not impair vision; acroparesthesia (50%-90%); angiokeratomas (10%-50%) that are usually <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> or sparse; and hypohidrosis. In addition, heterozygotes may have chronic abdominal pain and diarrhea [<a class="bk_pop" href="#fabry.REF.gupta.2005.261">Gupta et al 2005</a>].</p><p>With advancing age, heterozygotes may develop mild to moderate enlargement of the left heart (left ventricular hypertrophy) and valvular disease. More serious manifestations include significant left ventricular hypertrophy, cardiomegaly, myocardial ischemia, infarction, and cardiac arrhythmias [<a class="bk_pop" href="#fabry.REF.shah.2005.842">Shah et al 2005</a>, <a class="bk_pop" href="#fabry.REF.deegan.2006.347">Deegan et al 2006</a>, <a class="bk_pop" href="#fabry.REF.wilcox.2008.112">Wilcox et al 2008</a>].</p><p>The occurrence of cerebrovascular disease including transient ischemic attacks and cerebrovascular accidents is consistent with the microvascular pathology of the disease [<a class="bk_pop" href="#fabry.REF.macdermot.2001.769">MacDermot et al 2001</a>, <a class="bk_pop" href="#fabry.REF.whybra.2001.715">Whybra et al 2001</a>, <a class="bk_pop" href="#fabry.REF.galanos.2002.575">Galanos et al 2002</a>].</p><p>Renal findings in heterozygotes include isosthenuria, the presence of erythrocytes, leukocytes, and granular and hyaline casts in the urinary sediment, and proteinuria. According to the United States and European dialysis and transplantation registries, approximately 10% of heterozygotes develop renal failure requiring dialysis or transplantation.</p><p>Excessive guilt, fatigue, occupational difficulty, suicidal ideation, and depression have been noted in heterozygotes [<a class="bk_pop" href="#fabry.REF.sadek.2004.199">Sadek et al 2004</a>].</p><p><b>Life expectancy and cause of death.</b> Based on data from the Fabry Registry, 75 of 1422 males and 12 of 1426 females were reported to have died. The 87 deceased individuals were diagnosed at a much older age than other individuals in the Fabry Registry. The life expectancy of males with Fabry disease was 58.2 years, compared with 74.7 years in the general population of the United States. The life expectancy of females with Fabry disease was 75.4 years, compared with 80.0 years in the United States general population. The most common cause of death among both genders was cardiovascular disease [<a class="bk_pop" href="#fabry.REF.waldek.2009.790">Waldek et al 2009</a>]. Most individuals (57%) who died of cardiovascular disease had previously received renal replacement therapy (e.g., dialysis or transplantation). In the FOS, the principal causes of death among 181 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> relatives (most of whom had died before 2001) were renal failure in males (42%) and cerebrovascular disease in females (25%) [<a class="bk_pop" href="#fabry.REF.mehta.2009.548">Mehta et al 2009</a>]. In contrast, of the 42 individuals enrolled in the FOS whose deaths were reported between 2001 and 2007, cardiac disease was the main cause of death in both males (34%) and females (57%). The possible impact of ERT on life expectancy is discussed in Management, <a href="#fabry.Prevention_of_Primary_Manifestatio">Prevention of Primary Manifestations</a>.</p></div><div id="fabry.Atypical_Variants_of_Fabry_Disease"><h4>Atypical Variants of Fabry Disease</h4><p><b>Cardiac variant.</b> Males and females with cardiac disease are asymptomatic during most of their lives and typically present in the sixth to eighth decade of life with left ventricular hypertrophy, hypertrophic cardiomyopathy (HCM), conduction disturbances and arrhythmias. Screening of males with "late-onset" hypertrophic cardiomyopathy (HCM) found that 6.3% who were diagnosed at or after age 40 years and 1.4% of males who were diagnosed before age 40 years had Fabry disease confirmed by identification of low &#x003b1;-Gal A enzyme activity and a <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#fabry.REF.sachdev.2002.1407">Sachdev et al 2002</a>]. Magnetic resonance imaging of the heart typically shows late enhancement of the posterior wall with gadolinium reflecting posterior wall fibrosis demonstrated in postmortem specimens [<a class="bk_pop" href="#fabry.REF.moon.2003.2151">Moon et al 2003</a>]. The incidence of cardiac complications is similar in individuals with the atypical Fabry cardiac variant and individuals with classic Fabry disease [<a class="bk_pop" href="#fabry.REF.patel.2015.961">Patel et la 2015</a>].</p><p>Individuals with the cardiac variant exhibit mild to moderate proteinuria with normal renal function for age. Renal pathology is limited to glycosphingolipid deposition in podocytes, which is presumably responsible for their proteinuria. They generally do not develop renal failure.</p><p><b>Renal variant.</b> Renal variants were identified among individuals of Japanese ancestry on chronic hemodialysis in whom ESRD had been misdiagnosed as chronic glomerulonephritis [<a class="bk_pop" href="#fabry.REF.nakao.2003.801">Nakao et al 2003</a>]. Of note, five of the six individuals did not have angiokeratoma, acroparesthesia, hypohidrosis, or corneal opacities, but did have moderate to severe left ventricular hypertrophy. These observations indicated that the early symptoms of classic Fabry disease may not occur in individuals with the renal variant who develop renal insufficiency, and that the renal variant may be underdiagnosed. Therefore, it is appropriate to test individuals on renal dialysis and/or undergoing renal transplantation without a confirmed etiology of renal disease for Fabry disease.</p></div></div><div id="fabry.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Efforts to establish <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been limited because most families with Fabry disease have a <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, and there is significant phenotypic variability even among individuals with the same pathogenic variant.</p><ul><li class="half_rhythm"><div>Males with the classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have a variety of <i>GLA</i> variants, including large and small <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> rearrangements, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> defects, and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants [<a class="bk_pop" href="#fabry.REF.desnick.2001">Desnick et al 2001</a>, <a class="bk_pop" href="#fabry.REF.sch_fer.2005.412">Sch&#x000e4;fer et al 2005</a>, <a href="http://www.hgmd.cf.ac.uk/ac/index.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Human Gene Mutation Database</a>].</div></li><li class="half_rhythm"><div>Individuals with later-onset atypical variants (renal, cardiac, or cerebrovascular disease) have <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> or <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants that express residual &#x003b1;-Gal A enzyme activity [<a class="bk_pop" href="#fabry.REF.rolfs.2005.1794">Rolfs et al 2005</a>].</div></li><li class="half_rhythm"><div>A number of pathogenic variants including <a class="figpopup" href="/books/NBK1292/table/fabry.T.selected_gla_variants/?report=objectonly" target="object" rid-figpopup="figfabryTselectedglavariants" rid-ob="figobfabryTselectedglavariants">p.Arg112His</a>, <a class="figpopup" href="/books/NBK1292/table/fabry.T.selected_gla_variants/?report=objectonly" target="object" rid-figpopup="figfabryTselectedglavariants" rid-ob="figobfabryTselectedglavariants">p.Arg301Gln</a>, and <a class="figpopup" href="/books/NBK1292/table/fabry.T.selected_gla_variants/?report=objectonly" target="object" rid-figpopup="figfabryTselectedglavariants" rid-ob="figobfabryTselectedglavariants">p.Gly328Arg</a> have been identified in individuals with both the classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and the cardiac variant phenotype, suggesting that other modifying factors are involved in disease expression [<a class="bk_pop" href="#fabry.REF.ashtonprolla.2000.227">Ashton-Prolla et al 2000</a>].</div></li><li class="half_rhythm"><div>An analysis of the Fabry Outcome Survey (FOS) showed that disease manifestations in individuals with the <a class="figpopup" href="/books/NBK1292/table/fabry.T.selected_gla_variants/?report=objectonly" target="object" rid-figpopup="figfabryTselectedglavariants" rid-ob="figobfabryTselectedglavariants">p.Asn215Ser</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> were less severe than in age-matched individuals with Fabry disease caused by pathogenic variants associated with classic disease [<a class="bk_pop" href="#fabry.REF.schaefer.2005.87">Schaefer et al 2005</a>].</div></li><li class="half_rhythm"><div>Newborn screening in Taiwan has revealed a high prevalence (~1:1600 males) of individuals with the IVS4+919G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> where older family members with late-onset cardiac features have been found [<a class="bk_pop" href="#fabry.REF.lin.2009.450">Lin et al 2009</a>].</div></li></ul></div><div id="fabry.Prevalence"><h3>Prevalence</h3><p>The incidence of Fabry disease is estimated at 1:50,000 to 1:117,000 males [<a class="bk_pop" href="#fabry.REF.meikle.1999.249">Meikle et al 1999</a>, <a class="bk_pop" href="#fabry.REF.desnick.2001">Desnick et al 2001</a>].</p><p>Recent studies suggest that milder forms of the disease that present later in life and primarily affect the cardiovascular, cerebrovascular, or renal system may be more common and may be underdiagnosed.</p><p>A <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> study from Italy shows an incidence as high as 1:3,100, with an 11:1 ratio of persons with the later-onset/classic phenotypes [<a class="bk_pop" href="#fabry.REF.spada.2006.31">Spada et al 2006</a>]. The incidence of Fabry disease among nearly 35,000 neonates screened in Austria is 1:3859 [<a class="bk_pop" href="#fabry.REF.mechtler.2012.335">Mechtler et al 2012</a>].</p><p>In a study of the Taiwan Chinese population an unexpected high prevalence of the cardiac-variant Fabry-causing <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.640-801G&#x0003e;A (also known as IVS4+919G&#x0003e;A and c.639+919G&#x0003e;A) was found among newborns (~1:1600 males) as well as individuals with <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> hypertrophic cardiomyopathy [<a class="bk_pop" href="#fabry.REF.lin.2009.450">Lin et al 2009</a>].</p><p>Fabry disease is found among all ethnic, racial, and demographic groups.</p></div></div><div id="fabry.Genetically_Related_Allelic_Disord"><h2 id="_fabry_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> have been associated with pathogenic variants in <i>GLA</i>.</p></div><div id="fabry.Differential_Diagnosis"><h2 id="_fabry_Differential_Diagnosis_">Differential Diagnosis</h2><p>The pain of Fabry disease may be associated with a low-grade fever and an elevated erythrocyte sedimentation rate; these symptoms have frequently led to the misdiagnosis of rheumatic fever, neurosis, or <a href="/books/n/gene/etha/">erythromelalgia</a>.</p><p>Symptoms in individuals with Fabry disease are similar to those of other disorders including rheumatoid arthritis, juvenile arthritis, rheumatic fever, systemic lupus erythematosus (SLE), "growing pains," petechiae, Raynaud syndrome, early-onset stroke [<a class="bk_pop" href="#fabry.REF.cabrerasalazar.2005.102">Cabrera-Salazar et al 2005</a>, <a class="bk_pop" href="#fabry.REF.rolfs.2005.1794">Rolfs et al 2005</a>] and multiple sclerosis [<a class="bk_pop" href="#fabry.REF.callegaro.2006.27">Callegaro &#x00026; Kaimen-Maciel 2006</a>].</p><p>Males with Fabry disease may be unrecognized in cardiac clinics, where they are diagnosed with <a href="/books/n/gene/hyper-card/">hypertrophic cardiomyopathy</a>, and in nephrology clinics, where they are diagnosed with end-stage renal disease [<a class="bk_pop" href="#fabry.REF.bekri.2005.c33">Bekri et al 2005</a>, <a class="bk_pop" href="#fabry.REF.ichinose.2005.228">Ichinose et al 2005</a>, <a class="bk_pop" href="#fabry.REF.tanaka.2005.281">Tanaka et al 2005</a>].</p><p>Two studies have indicated that several individuals with <a href="/books/n/gene/fmf/">familial Mediterranean fever</a>, which can also cause pain and renal involvement, have been misdiagnosed as having Fabry disease [<a class="bk_pop" href="#fabry.REF.lidove.2012.571">Lidove et al 2012</a>, <a class="bk_pop" href="#fabry.REF.zizzo.2013.576">Zizzo et al 2013</a>].</p><p>Differential diagnosis of the cutaneous lesions must exclude the angiokeratoma of Fordyce spots, angiokeratoma of Mibelli, and angiokeratoma circumscriptum, none of which has the typical histologic or ultrastructural lysosomal storage pathology of the Fabry lesion:</p><ul><li class="half_rhythm"><div>Angiokeratoma of Fordyce is characterized by spots similar in appearance to those of Fabry disease but limited to the scrotum and usually appearing after age 30 years.</div></li><li class="half_rhythm"><div>Angiokeratoma of Mibelli is characterized by warty lesions on the extensor surfaces of extremities in young adults and associated with erythematous subcutaneous swellings (chilblains).</div></li><li class="half_rhythm"><div>Angiokeratoma circumscriptum or naeviforme can occur anywhere on the body, is clinically and histologically similar to angiokeratoma of Fordyce, and is not associated with chilblains.</div></li></ul><p>Angiokeratomas, in clinical appearance and distribution reportedly similar to or indistinguishable from the cutaneous lesions seen in individuals with Fabry disease, have been described in individuals with other lysosomal storage diseases, including fucosidosis, sialidosis (&#x003b1;-neuraminidase deficiency with or without &#x003b2;-galactosidase deficiency), adult-type &#x003b2;-galactosidase deficiency, aspartylglucosaminuria, adult-onset &#x003b1;-galactosidase B deficiency, &#x003b2;-mannosidase deficiency, and a lysosomal disorder with intellectual disability and some features of the mucopolysaccharidoses [<a class="bk_pop" href="#fabry.REF.desnick.2001">Desnick et al 2001</a>].</p></div><div id="fabry.Management"><h2 id="_fabry_Management_">Management</h2><div id="fabry.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Fabry disease, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Careful history for evidence of acroparesthesia, sweating abnormalities (i.e., hypohidrosis), or other manifestations of the disorder</div></li><li class="half_rhythm"><div>Renal function studies, including BUN, creatinine, and urinalysis</div></li><li class="half_rhythm"><div>Cardiac evaluation, including echocardiography</div></li><li class="half_rhythm"><div>Examination of the skin for angiokeratomas</div></li><li class="half_rhythm"><div>Formal audiology assessment</div></li><li class="half_rhythm"><div>Ophthalmologic evaluation</div></li><li class="half_rhythm"><div>Neurologic assessment</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="fabry.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Acroparesthesia</b></p><ul><li class="half_rhythm"><div><b>Diphenylhydantoin.</b> The severe pain of such episodes in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females often responds to low-maintenance doses of diphenylhydantoin by reducing the frequency and severity of the periodic crises of excruciating pain and constant discomfort. A potential side effect of diphenylhydantoin is gingival hypertrophy.</div></li><li class="half_rhythm"><div><b>Carbamazepine</b> has similar effects. The combination of the two drugs may also significantly reduce the frequency and severity of the pain. Dose-related autonomic complications with carbamazepine include urinary retention, nausea, vomiting, and ileus.</div></li><li class="half_rhythm"><div><b>Gabapentin</b> has been demonstrated to improve pain [<a class="bk_pop" href="#fabry.REF.ries.2003.413">Ries et al 2003</a>].</div></li></ul><p><b>Renal disease.</b> Renal insufficiency is the most frequent and serious late complication in males with the classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) should be used in those with evidence of renal involvement, especially to reduce proteinuria [<a class="bk_pop" href="#fabry.REF.waldek.2014.72">Waldek &#x00026; Feriozzi 2014</a>, <a class="bk_pop" href="#fabry.REF.warnock.2015.860">Warnock et al 2015</a>].</p><p>Chronic hemodialysis and/or renal transplantation have become lifesaving procedures. The engrafted kidney remains histologically free of glycosphingolipid deposition because the normal alpha-galactosidase A (&#x003b1;-Gal A) enzyme activity in the allograft catabolizes endogenous renal glycosphingolipid substrates. Therefore, successful renal transplantation corrects renal function.</p><p>Reviews of the registries of the European Renal Association-European Dialysis and Transplantation Association and the United States Renal Data System support excellent outcomes for renal transplantation in individuals with Fabry disease. For example, during the ten-year period from 1988 to 1998, 93 individuals who underwent renal transplantation were reported to the US registry. Compared to a matched control group, recipients with Fabry disease had equivalent five-year life survival (82% vs 83%) and graft survival (67% vs 75%), respectively.</p><p>Note: (1) Immune function in males with Fabry disease is similar to that in other individuals with uremia, obviating any immunologic contraindication to transplantation in this disease. Autoimmune conditions have, however, been reported to occur at an increased frequency in individuals with Fabry disease [<a class="bk_pop" href="#fabry.REF.martinez.2007.365">Martinez et al 2007</a>]. (2) Transplantation of kidneys from female heterozygotes should be avoided, as the organs may already contain significant substrate deposition; all related potential donors must be evaluated to exclude <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females.</p></div><div id="fabry.Prevention_of_Primary_Manifestatio"><h3>Prevention of Primary Manifestations</h3><p><b>Enzyme replacement therapy (ERT).</b> The two ERTs using recombinant or <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-activated human &#x003b1;-Gal A enzyme that have been evaluated in clinical trials are Fabrazyme<sup>&#x000ae;</sup> (agalsidase beta 1 mg/kg every 2 weeks) and Replagal&#x02122; (agalsidase alfa 0.2 mg/kg every 2 weeks). Both were approved in 2001 by the European Agency for Evaluation of Medical Products; only Fabrazyme<sup>&#x000ae;</sup> was approved by the FDA for use in the United States.</p><p>The following is a summary of some of the clinical trials for each drug:</p><ul><li class="half_rhythm"><div>Single-center double-blind placebo-controlled studies of agalsidase alfa have shown a beneficial effect of ERT on neuropathic pain [<a class="bk_pop" href="#fabry.REF.schiffmann.2001.2743">Schiffmann et al 2001</a>] and left ventricular hypertrophy [<a class="bk_pop" href="#fabry.REF.hughes.2008.153">Hughes et al 2008</a>]. Data from the Fabry Outcome Survey (FOS) suggest that ERT with agalsidase alfa improves pain and quality of life, reduces the natural rate of decline of renal and cardiac function in males and females with Fabry disease [<a class="bk_pop" href="#fabry.REF.mehta.2009.548">Mehta et al 2009</a>] and may improve life expectancy [<a class="bk_pop" href="#fabry.REF.beck.2015.21">Beck et al 2015</a>]. The enzyme is safe in children [<a class="bk_pop" href="#fabry.REF.ramaswami.2006.86">Ramaswami et al 2006</a>]. In persons with advanced renal disease, weekly administration of 0.2 mg/kg agalsidase alfa may be associated with a slower decline in renal function [<a class="bk_pop" href="#fabry.REF.schiffmann.2007.1576">Schiffmann et al 2007</a>, <a class="bk_pop" href="#fabry.REF.schiffmann.2015.1129">Schiffmann et al 2015</a>].</div></li><li class="half_rhythm"><div>A double-blind, randomized, placebo-controlled study of agalsidase beta demonstrated increased clearance of globotriaosylceramide (GL-3) from the endothelial cells of the kidney, heart, and skin among treated subjects [<a class="bk_pop" href="#fabry.REF.eng.2001.9">Eng et al 2001</a>].</div></li><li class="half_rhythm"><div>A Phase IV extension study showed that the risk of major clinical events (a combination of death, myocardial infarction, stroke, development of ESRD, or a 33% increase in serum creatinine concentration) was reduced by 53% with agalsidase beta treatment after adjustment for baseline proteinuria (P=0.06) [<a class="bk_pop" href="#fabry.REF.banikazemi.2007.77">Banikazemi et al 2007</a>]. In a ten-year follow up of these individuals, with additional data from the Fabry Registry, <a class="bk_pop" href="#fabry.REF.germain.2015.353">Germain et al [2015]</a> reported that 49 of 52 were alive and 42/52 (81%) did not experience any severe clinical events during the ten-year treatment interval. Disease progression was most likely to be observed in those individuals who initiated treatment after age 40 years and/or had advanced renal disease at baseline. A study of cardiac outcomes from the Fabry Registry of 115 males treated with agalsidase beta for at least two years reports that treated individuals fared better than 48 untreated males. Left ventricular mass fell at a slope of -3.6 g/year in 31 males aged 18-30 years but rose by 9.5 g/year in 15 males who were not treated [<a class="bk_pop" href="#fabry.REF.germain.2013.958">Germain et al 2013</a>].</div></li><li class="half_rhythm"><div>The largest comparative study is the Canadian Fabry Disease initiative. <a class="bk_pop" href="#fabry.REF.sirrs.2014.499">Sirrs et al [2014]</a> have reported five-year follow-up data on 362 subjects for a composite endpoint (death, neurologic or cardiovascular events, development of ESRD, or sustained increase in serum creatinine of 50% from baseline). Ninety-two of 178 individuals treated with ERT were randomly allocated to either agalsidase alfa or agalsidase beta. No differences were found with regard to the clinical efficacy of the two medications, and individuals who switched from agalsidase beta to agalsidase alfa during the time of Fabrazyme<sup>&#x000ae;</sup> shortage were stable. In comparison with the placebo group in the Banikazemi study individuals treated with ERT had a significant reduction in clinical events, which occurred at an older age. The eight-year follow-up data continued to suggest that the two medications are equivalent at their standard doses [M West, personal communication].</div></li><li class="half_rhythm"><div>Antibody formation has been reported with both agalsidase alfa and agalsidase beta in males, but not females [<a class="bk_pop" href="#fabry.REF.linthorst.2005.201">Linthorst et al 2005</a>, <a class="bk_pop" href="#fabry.REF.wilcox.2012.443">Wilcox et al 2012</a>]. <a class="bk_pop" href="#fabry.REF.lenders.2015.1009">Lenders et al [2015]</a> reported that 40% of 68 males with Fabry disease on ERT have evidence of serum-mediated inhibition of agalsidase activity. They further reported that inhibition-positive individuals have worse clinical outcomes and higher levels of lyso-Gb3 than inhibition-negative individuals. There appeared to be no difference between agalsidase alfa and beta with regard to the development of serum inhibitors. The impact of antibody formation on the overall efficacy of treatment is currently unknown.</div></li><li class="half_rhythm"><div>During 2009-2012, a shortage of agalsidase beta resulted in the substitution of agalsidase alfa for agalsidase beta in several cohorts of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Reports thus far have not indicated any significant difference in clinical parameters as a result of this transition [<a class="bk_pop" href="#fabry.REF.smid.2011.69">Smid et al 2011</a>, <a class="bk_pop" href="#fabry.REF.tsuboi.2012.779">Tsuboi &#x00026; Yamamoto 2012</a>, <a class="bk_pop" href="#fabry.REF.pisani.2013.41">Pisani et al 2013</a>, <a class="bk_pop" href="#fabry.REF.gokeralpan.2016.95">Goker-Alpan et al 2016</a>].</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#fabry.REF.lubanda.2009.256">Lubanda et al [2009]</a> have shown in a small study of 21 individuals that those who have been &#x02018;stabilized&#x02019; with agalsidase beta at 1 g/kg can thereafter be safely treated with a maintenance dose of 0.3 g/kg every other week. A study of lower-dose agalsidase beta has been conducted in children (FIELD study [<a class="bk_pop" href="#fabry.REF.wijburg.2015.e0124987">Wijburg et al 2015</a>]); it will be interesting to observe if lower doses of agalsidase beta are equally efficacious in children.</div></li></ul><p>There is an emerging consensus that ERT has, at best, a limited impact on the long-term outcome of Fabry disease. Studies of consecutive <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons from individual centers suggest that cardiac, renal, and cerebrovascular outcomes are comparable among treated and untreated cohorts [<a class="bk_pop" href="#fabry.REF.rombach.2013.29">Rombach et al 2013</a>, <a class="bk_pop" href="#fabry.REF.weidemann.2013.331">Weidemann et al 2013</a>]. A recent Cochrane review has also highlighted the generally poor quality of evidence in favor of ERT for Fabry disease.</p><p>Despite these emerging data, a panel of physician experts have recommended that ERT be initiated as early as possible in all males with Fabry disease, including children and those with ESRD undergoing dialysis and renal transplantation, and in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females with significant disease [<a class="bk_pop" href="#fabry.REF.desnick.2003.338">Desnick et al 2003</a>, <a class="bk_pop" href="#fabry.REF.eng.2006.539">Eng et al 2006</a>] because all are at high risk for cardiac, cerebrovascular, and neurologic complications including transient ischemic attacks and strokes. The treatment initiation guidelines from a group of European physicians are generally more conservative [<a class="bk_pop" href="#fabry.REF.biegstraaten.2015.36">Biegstraaten et al 2015</a>]. They emphasize the need to start ERT before the advent of irreversible complications and suggest that initiation of ERT after irreversible organ damage has occurred is to be avoided. ERT should be discontinued if it is making no impact on organ function in an individual; and compliance should be closely monitored.</p></div><div id="fabry.Prevention_of_Secondary_Complicati"><h3>Prevention of Secondary Complications</h3><p>The prophylaxis for renovascular disease, ischemic heart disease, and cerebrovascular disease in persons with Fabry disease is the same as for the general population.</p><ul><li class="half_rhythm"><div>Proteinuria/microalbuminuria should be minimized with ACE inhibitors/ARBs [<a class="bk_pop" href="#fabry.REF.tahir.2007.2609">Tahir et al 2007</a>]; blood pressure control optimized; and cholesterol normalized [<a class="bk_pop" href="#fabry.REF.waldek.2014.72">Waldek &#x00026; Feriozzi 2014</a>].</div></li><li class="half_rhythm"><div>Aspirin and other anti-platelet agents such as clopidogrel may be recommended for the prophylaxis of stroke.</div></li><li class="half_rhythm"><div>Although evidence as to the effect on long-term outcomes is lacking, use of aspirin and lipid-lowering agents and optimal blood pressure control are recommended in persons with symptoms of cardiac ischemia [<a class="bk_pop" href="#fabry.REF.eng.2006.539">Eng et al 2006</a>].</div></li></ul><p>The role of ERT in the long-term prophylaxis of renal, cardiac, and CNS manifestations is unproven; however, on the basis of stabilization of organ function in persons with more advanced disease, some have suggested the initiation of ERT in early disease stages: at first sign of disease manifestations in boys; at age 12-13 years in asymptomatic boys; and at the time of diagnosis in adult males [<a class="bk_pop" href="#fabry.REF.eng.2006.539">Eng et al 2006</a>]. Studies indicate that late initiation of therapy when renal or cardiac manifestations are significant is associated with less effect than initiation earlier in the disease course [<a class="bk_pop" href="#fabry.REF.germain.2015.353">Germain et al 2015</a>, <a class="bk_pop" href="#fabry.REF.ortiz.2016.495">Ortiz et al 2016</a>].</p></div><div id="fabry.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Annual or more frequent renal function studies</div></li><li class="half_rhythm"><div>Annual cardiology evaluation</div></li><li class="half_rhythm"><div>Annual audiology evaluation</div></li><li class="half_rhythm"><div>Biennial brain MRI/MRA</div></li></ul></div><div id="fabry.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The obstructive lung disease, which has been documented in older <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> males and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females, is more severe in smokers; therefore, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals should be discouraged from smoking.</p><p>Amiodarone has been reported to induce cellular and biochemical changes resulting in a phenocopy in particular of the keratopathy of Fabry disease [<a class="bk_pop" href="#fabry.REF.whitley.1983.2177">Whitley et al 1983</a>]. Given potential effects on cellular levels of &#x003b1;-Gal A enzyme activity, it has been contraindicated in persons with Fabry disease. However, little evidence of a detrimental effect in this specific group exists and the relative benefit in individuals with cardiac arrhythmia should be considered.</p></div><div id="fabry.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate apparently asymptomatic older and younger at-risk male and female relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from initiation of treatment (ERT) and preventive measures.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known:</div><ul><li class="half_rhythm"><div><b>Males.</b> Measure &#x003b1;-Gal A enzyme activity.</div></li><li class="half_rhythm"><div><b>Females.</b> Measurement of &#x003b1;-Gal A enzyme activity is unreliable in females although demonstration of decreased &#x003b1;-Gal A enzyme activity is diagnostic of the <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> state. Ophthalmologic examination for the characteristic whorl-like corneal opacities by slit-lamp microscopy can be considered if enzyme analysis is uninformative. However, only 80%-90% of heterozygous females have the corneal lesions.</div></li></ul></li></ul><p>See <a href="#fabry.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="fabry.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p><b>Gene replacement therapy</b> has been investigated in the mouse model of Fabry disease [<a class="bk_pop" href="#fabry.REF.ziegler.1999.1667">Ziegler et al 1999</a>, <a class="bk_pop" href="#fabry.REF.ziegler.2002.935">Ziegler et al 2002</a>, <a class="bk_pop" href="#fabry.REF.ziegler.2004.231">Ziegler et al 2004</a>]. A trial of <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> via autologous stem cell transplantation is currently in progress in Canada.</p><p><b>Chaperone therapy,</b> a novel approach, uses small molecules designed to enhance the residual enzyme activity by protecting the mutated enzyme from misfolding and degradation in the cell [<a class="bk_pop" href="#fabry.REF.desnick.2002.954">Desnick &#x00026; Schuchman 2002</a>]. A report of chaperone therapy in a male with the cardiac variant demonstrated the "proof of concept" for this therapeutic strategy for Fabry disease [<a class="bk_pop" href="#fabry.REF.frustaci.2001.25">Frustaci et al 2001</a>].</p><p>Phase I trials have demonstrated elevation of plasma &#x003b1;-Gal A levels in healthy volunteers [<a class="bk_pop" href="#fabry.REF.fan.1999.112">Fan et al 1999</a>, <a class="bk_pop" href="#fabry.REF.ishii.2004.250">Ishii et al 2004</a>]. Phase III trials are now in progress in males and females with Fabry disease with a pharmacologic chaperone (1-deoxygalactonojirimycin; DGJ; Migalastat Amicus Therapeutics, NJ, USA). DGJ has been demonstrated to enhance trafficking of mutated &#x003b1;-Gal A to lysosomes of fibroblasts derived from persons with Fabry disease and to increase enzyme activity while reducing GL-3 substrate in tissues of a transgenic/knockout animal model of Fabry disease. In 2016 Migalastat received marketing approval in the European Union.</p><p><b>Alternative enzyme therapy.</b> A PEGylated version of recombinant &#x003b1;-Gal A with a longer circulating half-life is currently in a Phase II trial.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div><div id="fabry.Other"><h3>Other</h3><p>Substrate reduction therapy for Fabry disease has a biochemical rationale. Clinical trials of substrate reduction therapy will be commencing soon.</p></div></div><div id="fabry.Genetic_Counseling"><h2 id="_fabry_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="fabry.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Fabry disease is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div><div id="fabry.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div class="half_rhythm">In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male individual is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>).</div><div class="half_rhythm">Note: If a woman has more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child and no other affected relatives and the <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> should be considered as a possible explanation.</div></li><li class="half_rhythm"><div class="half_rhythm">If only one individual in the family is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the mother of the affected male is likely <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Rarely, an affected male may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant, in which case the mother is not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</div></li></ul><p><b>Sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be will be heterozygotes and may be symptomatic. See Clinical Description, <a href="#fabry.Heterozygous_Carrier_Females">Heterozygous (Carrier) Females</a>.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the theoretic possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Sibs of a (symptomatic or asymptomatic) <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female</b></p><ul><li class="half_rhythm"><div>If the father of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, he will transmit it to all his daughters and none of his sons.</div></li><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be heterozygotes (carriers) and may be symptomatic. See <a href="#fabry.Heterozygous_Carrier_Females">Heterozygous (Carrier) Females</a>.</div></li><li class="half_rhythm"><div>Paternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> has been demonstrated in this condition [<a class="bk_pop" href="#fabry.REF.dobrovoln_.2005.84">Dobrovoln&#x000fd; et al 2005</a>]. Thus, even if the <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has not been identified in paternal leukocyte DNA, female sibs of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female may still be at increased risk of inheriting the pathogenic variant.</div></li></ul><p><b>Offspring of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male.</b> Affected males transmit the <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to:</p><ul><li class="half_rhythm"><div>All of their daughters who will be heterozygotes and may be symptomatic. See <a href="#fabry.Heterozygous_Carrier_Females">Heterozygous (Carrier) Females</a>.</div></li><li class="half_rhythm"><div>None of their sons.</div></li></ul><p><b>Offspring of a (symptomatic or asymptomatic) <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female.</b> Women with a <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a 50% chance of transmitting the pathogenic variant to each child:</p><ul><li class="half_rhythm"><div>Males who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div>Females who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be heterozygotes and may be symptomatic. See <a href="#fabry.Heterozygous_Carrier_Females">Heterozygous (Carrier) Females</a>.</div></li></ul><p><b>Other family members.</b> The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts may be at risk of being heterozygotes and the aunts' offspring, depending on their gender, may be at risk of being heterozygotes and/or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. At-risk females should be offered clinical examination, <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>, and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div id="fabry.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p><b>Molecular genetic testing</b> of at-risk female relatives to determine their genetic status is most informative if the <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><p><b>Measurement of alpha-galactosidase A (&#x003b1;-Gal A) enzyme activity</b> is unreliable for <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> detection. Although demonstration of decreased &#x003b1;-Gal A activity in a female is diagnostic of the <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> state, some heterozygotes have &#x003b1;-Gal A activity in the normal range.</p><p><b>Ophthalmologic examination</b> for the characteristic whorl-like corneal opacities by slit-lamp microscopy can be considered if enzyme analysis is uninformative and the specific <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family has not been identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. However, only 80%-90% of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females have the corneal lesions.</p></div><div id="fabry.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>Fabry disease practice guidelines are available. See <a href="http://link.springer.com/article/10.1007%2Fs10897-013-9613-3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors</a> [<a class="bk_pop" href="#fabry.REF.laney.2013">Laney et al 2013</a>].</p><p>See Management, <a href="#fabry.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of genetic status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="fabry.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p><b>Biochemical testing.</b> If the <a class="def" href="/books/n/gene/glossary/def-item/karyotype/">karyotype</a> is 46,XY, &#x003b1;-Gal A enzyme activity can be measured in fetal cells. (If the <i>GLA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, a biochemical diagnosis can be confirmed by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of fetal DNA.)</p></div></div><div id="fabry.Resources"><h2 id="_fabry_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Fabry Support and Information Group (FSIG)</b></div><div>108 NE 2nd Street</div><div>Suite C</div><div>PO Box 510</div><div>Concordia MO 64020</div><div><b>Phone:</b> 660-463-1355</div><div><b>Fax:</b> 660-463-1356</div><div><b>Email:</b> info@fabry.org</div><div><a href="http://www.fabry.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fabry.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Fabry%20disease&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fabry disease</a></div></li><li class="half_rhythm"><div><b>National Fabry Disease Foundation (NFDF)</b></div><div>4301 Connecticut Avenue Northwest</div><div>Suite 404</div><div>Washington DC 20008-2369</div><div><b>Phone:</b> 800-651-9131 (toll-free)</div><div><b>Fax:</b> 800-651-9135 (toll-free)</div><div><b>Email:</b> info@fabrydisease.org</div><div><a href="https://www.fabrydisease.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fabrydisease.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=fabrydisease" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fabry disease</a></div></li><li class="half_rhythm"><div><b>Canadian MPS Society</b></div><div>#218-2055 Commercial Drive</div><div>Vancouver British Columbia V5N 0C7</div><div>Canada</div><div><b>Phone:</b> 800-667-1846; 604-924-5130</div><div><b>Email:</b> info@mpssociety.ca</div><div><a href="http://www.mpssociety.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mpssociety.ca</a></div></li><li class="half_rhythm"><div><b>National Tay-Sachs and Allied Diseases Association, Inc. (NTSAD)</b></div><div>2001 Beacon Street</div><div>Suite 204</div><div>Boston MA 02135</div><div><b>Phone:</b> 800-906-8723 (toll-free)</div><div><b>Fax:</b> 617-277-0134</div><div><b>Email:</b> info@ntsad.org</div><div><a href="http://www.ntsad.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ntsad.org</a></div></li><li class="half_rhythm"><div><b>Society for Mucopolysaccharide Diseases (MPS)</b></div><div>MPS House Repton Place</div><div>White Lion Road</div><div>Amersham Buckinghamshire HP7 9LP</div><div>United Kingdom</div><div><b>Phone:</b> 0345 389 9901</div><div><b>Email:</b> mps@mpssociety.co.uk</div><div><a href="http://www.mpssociety.co.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mpssociety.co.uk</a></div></li><li class="half_rhythm"><div><b>RegistryNXT!</b></div><div><b>Phone:</b> 888-404-4413</div><div><b>Email:</b> RegistryNXT.helpdesk@us.imshealth.com</div><div><a href="https://www.registrynxt.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.registrynxt.com</a></div></li></ul></div><div id="fabry.Molecular_Genetics"><h2 id="_fabry_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="fabry.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Fabry Disease: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1292/table/fabry.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fabry.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_fabry.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_fabry.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_fabry.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_fabry.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_fabry.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_fabry.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_fabry.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2717" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>GLA</i></a></td><td headers="hd_b_fabry.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2717" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq22<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_fabry.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P06280" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alpha-galactosidase A</a></td><td headers="hd_b_fabry.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/GLA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GLA @ LOVD</a><br /><a href="https://research.cchmc.org/LOVD2/home.php?select_db=GLA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (GLA)</a></td><td headers="hd_b_fabry.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GLA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GLA</a></td><td headers="hd_b_fabry.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=GLA[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GLA</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="fabry.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="fabry.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Fabry Disease (<a href="/omim/300644,301500" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1292/table/fabry.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fabry.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300644" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300644</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GALACTOSIDASE, ALPHA; GLA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/301500" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">301500</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FABRY DISEASE</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>GLA</i> spans approximately 13 kb of <a class="def" href="/books/n/gene/glossary/def-item/gdna/">gDNA</a> and contains seven exons; the <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> is 1290 bases and encodes a polypeptide of 429 amino acids including a 31-amino acid signal peptide. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1292/#fabry.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> The variant p.Asp313Tyr, a common <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 6 variant with decreased activity in vitro and reduced activity at neutral pH resulting in low plasma alpha-galactosidase A (&#x003b1;-Gal A) activity, has been identified in 0.45% of normal individuals (n = 800 alleles). Expression of p.Asp313Tyr in COS-7 cells resulted in approximately 60% of wild type enzymatic activity and showed normal lysosomal localization [<a class="bk_pop" href="#fabry.REF.froissart.2003.307">Froissart et al 2003</a>, <a class="bk_pop" href="#fabry.REF.yasuda.2003.162">Yasuda et al 2003</a>]. Thus, p.Asp313Tyr is a variant that does not cause Fabry disease.</p><p><b>Pathogenic variants.</b> More than 800 <i>GLA</i> pathogenic variants have been identified, and most are family specific, occurring only in single pedigrees. Affected males with frameshift and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants typically present with classic Fabry disease; males with <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> pathogenic variants can present with either classic or atypical phenotypes [<a class="bk_pop" href="#fabry.REF.pan.2016.e0161330">Pan et al 2016</a>].</p><p><i>GLA</i> pathogenic variants that result in residual &#x003b1;-gal A activity of about 20% have been identified in individuals with atypical variants of Fabry disease. The clinical manifestations of atypical cases are not specific to Fabry disease (e.g., stroke, cardiomyopathy); therefore, the pathogenicity of some variants is unclear [<a class="bk_pop" href="#fabry.REF.lukas.2016.43">Lukas et al 2016</a>]. A number of variants including p.Ile91Thr, p.Arg112His, p.Phe113Leu, p.Asn215Ser, p.Met296Ile, p.Arg301Gln, and p.Gly328Arg are recurrent and associated with late-onset cardiac disease [<a class="bk_pop" href="#fabry.REF.patel.2015.961">Patel et al 2015</a>]. Most individuals with the IVS4+919G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> were not diagnosed until <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> identified this variant in their grandsons [<a class="bk_pop" href="#fabry.REF.liu.2015.107">Liu et al 2015</a>].</p><p>The pathogenicity of some <i>GLA</i> variants is disputed. The p.Arg118Cys variant has been recurrently described in large Fabry disease screening studies of high-risk individuals; however, this variant does not always segregate with Fabry disease in a Mendelian fashion, and could be a modulator of cerebrovascular disease risk [<a class="bk_pop" href="#fabry.REF.ferreira.2015.248">Ferreira et al 2015</a>]. The p.Ala143Thr variant has been associated with renal failure, stroke, and left ventricular hypertrophy which could potentially be the result of selection bias, as most individuals were detected in screening studies [<a class="bk_pop" href="#fabry.REF.terryn.2013.101">Terryn et al 2013</a>].</p><div id="fabry.T.selected_gla_variants" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>GLA</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1292/table/fabry.T.selected_gla_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fabry.T.selected_gla_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fabry.T.selected_gla_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_fabry.T.selected_gla_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide<br />Change</th><th id="hd_h_fabry.T.selected_gla_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein<br />Change</th><th id="hd_h_fabry.T.selected_gla_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference<br />Sequences</th></tr></thead><tbody><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.937G&#x0003e;T</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp313Tyr</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_4" rowspan="12" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000169.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000169<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_000160.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000160<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Uncertain</b></td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.352C&#x0003e;T</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg118Cys</td></tr><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.427G&#x0003e;A</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala143Thr</td></tr><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_1" rowspan="9" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.272T&#x0003e;C</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile91Thr</td></tr><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.335G&#x0003e;A</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg112His&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.337T&#x0003e;C</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe113Leu</td></tr><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.427G&#x0003e;C</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala143Pro</td></tr><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.640-801G&#x0003e;A (IVS4+919G&#x0003e;A; c.639+919G&#x0003e;A)</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.644A&#x0003e;G</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn215Ser</td></tr><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.888G&#x0003e;A</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met296Ile</td></tr><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.902G&#x0003e;A</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg301Gln&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.982G&#x0003e;A</td><td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly328Arg&#x000a0;<sup>1</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="fabry.TF.3.1"><p class="no_margin">See <a href="#fabry.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Alpha-galactosidase A (&#x003b1;-Gal A) is a lysosomal exoglycohydrolase. The mature &#x003b1;-Gal A enzyme polypeptide is 398 amino acids and contains three functional N-glycosylation sites. The active enzyme is a homodimer of approximately 101 kd.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>GLA</i> pathogenic variants result in <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> instability and/or severely truncated &#x003b1;-Gal A or an enzyme with markedly decreased activity.</p></div><div id="fabry.References"><h2 id="_fabry_References_">References</h2><div id="fabry.Published_Guidelines__Consensus_St"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.bennett.2002">Bennett RL, Hart KA, O Rourke E, Barranger JA, Johnson J, MacDermot KD, Pastores GM, Steiner RD, Thadhani R. Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors (pdf). Available <a href="http://www.springerlink.com/content/pd2ejhrnrwtxac20/fulltext.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2002. Accessed 2-20-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.gal.2011">Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. Available <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063537/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2011. Accessed 2-20-19. [<a href="/pmc/articles/PMC3063537/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3063537</span></a>] [<a href="/pubmed/21229318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21229318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.laney.2013">Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J, O'Rourke E, Sims K, Walter G. Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors. Available <a href="http://link.springer.com/article/10.1007%2Fs10897-013-9613-3" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 2-20-19.</div></li></ul></div><div id="fabry.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.aerts.2008.2812">Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2008;<span class="ref-vol">105</span>:2812–7.</span> [<a href="/pmc/articles/PMC2268542/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2268542</span></a>] [<a href="/pubmed/18287059" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18287059</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.allen.2010.1602">Allen LE, Cosgrave EM, Kersey JP, Ramaswami U. Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity. <span><span class="ref-journal">Br J Ophthalmol. </span>2010;<span class="ref-vol">94</span>:1602–5.</span> [<a href="/pubmed/20576773" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20576773</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.ashtonprolla.2000.227">Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. <span><span class="ref-journal">J Investig Med. </span>2000;<span class="ref-vol">48</span>:227–35.</span> [<a href="/pubmed/10916280" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10916280</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.aurayblais.2015.195">Auray-Blais C, Blais CM, Ramaswami U, Boutin M, Germain DP, Dyack S, Bodamer O, Pintos-Morell G, Clarke JT, Bichet DG, Warnock DG, Echevarria L, West ML, Lavoie P. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. <span><span class="ref-journal">Clin Chim Acta. </span>2015;<span class="ref-vol">438</span>:195–204.</span> [<a href="/pubmed/25149322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25149322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.banikazemi.2007.77">Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. <span><span class="ref-journal">Ann Intern Med. </span>2007;<span class="ref-vol">146</span>:77–86.</span> [<a href="/pubmed/17179052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17179052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.beck.2015.21">Beck M, Hughes D, Kampmann C, Larroque S, Mehta A, Pintos-Morell G, Ramaswami U, West M, Wijatyk A, Giugliani R., Fabry Outcome Survey Study Group.  Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis. <span><span class="ref-journal">Mol Genet Metab Rep. </span>2015;<span class="ref-vol">3</span>:21–7.</span> [<a href="/pmc/articles/PMC4750577/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4750577</span></a>] [<a href="/pubmed/26937390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26937390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.bekri.2005.c33">Bekri S, Enica A, Ghafari T, Plaza G, Champenois I, Choukroun G, Unwin R, Jaeger P. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. <span><span class="ref-journal">Nephron Clin Pract. </span>2005;<span class="ref-vol">101</span>:c33–8.</span> [<a href="/pubmed/15886492" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15886492</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.bernstein.1989.1390">Bernstein HS, Bishop DF, Astrin KH, Kornreich R, Eng CM, Sakuraba H, Desnick RJ. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. <span><span class="ref-journal">J Clin Invest. </span>1989;<span class="ref-vol">83</span>:1390–9.</span> [<a href="/pmc/articles/PMC303833/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC303833</span></a>] [<a href="/pubmed/2539398" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2539398</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.biegstraaten.2015.36">Biegstraaten M, Arngr&#x000ed;msson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, Rudnicki M, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, T&#x000f8;ndel C, Vujkovac B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2015;<span class="ref-vol">10</span>:36.</span> [<a href="/pmc/articles/PMC4383065/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4383065</span></a>] [<a href="/pubmed/25885911" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25885911</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.brouns.2010.863">Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, Redondo P, Hemelsoet D, Fumal A, Jeangette S, Verslegers W, Baker R, Hughes D, De Deyn PP. BeFaS Investigators. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. <span><span class="ref-journal">Stroke. </span>2010;<span class="ref-vol">41</span>:863–8.</span> [<a href="/pubmed/20360539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20360539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.cabrerasalazar.2005.102">Cabrera-Salazar MA, O'Rourke E, Charria-Ortiz G, Barranger JA. Radiological evidence of early cerebral microvascular disease in young children with Fabry disease. <span><span class="ref-journal">J Pediatr. </span>2005;<span class="ref-vol">147</span>:102–5.</span> [<a href="/pubmed/16027705" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16027705</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.callegaro.2006.27">Callegaro D, Kaimen-Maciel DR. Fabry's disease as a differential diagnosis of MS. <span><span class="ref-journal">Int MS J. </span>2006;<span class="ref-vol">13</span>:27–30.</span> [<a href="/pubmed/16420782" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16420782</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.cole.2007.943">Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH. Depression in adults with Fabry disease: a common and under-diagnosed problem. <span><span class="ref-journal">J Inherit Metab Dis. </span>2007;<span class="ref-vol">30</span>:943–51.</span> [<a href="/pubmed/17994284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17994284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.deegan.2006.347">Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:347–52.</span> [<a href="/pmc/articles/PMC2563231/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2563231</span></a>] [<a href="/pubmed/16227523" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16227523</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.desnick.2003.338">Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. <span><span class="ref-journal">Ann Intern Med. </span>2003;<span class="ref-vol">138</span>:338–46.</span> [<a href="/pubmed/12585833" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12585833</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.desnick.2001">Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B, eds. <em>The Metabolic and Molecular Bases of Inherited Diseases</em>. 8 ed. New York, NY: McGraw-Hill; 2001:3733-74.</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.desnick.2002.954">Desnick RJ, Schuchman EH. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. <span><span class="ref-journal">Nat Rev Genet. </span>2002;<span class="ref-vol">3</span>:954–66.</span> [<a href="/pubmed/12459725" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12459725</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.dobrovoln_.2005.84">Dobrovoln&#x000fd; R, Dvor&#x000e1;kov&#x000e1; L, Ledvinov&#x000e1; J, Magage S, Bultas J, Lubanda JC, Poupetov&#x000e1; H, Elleder M, Karetov&#x000e1; D, Hreb&#x000ed;cek M. Recurrence of Fabry disease as a result of paternal germline mosaicism for alpha-galactosidase a gene mutation. <span><span class="ref-journal">Am J Med Genet A. </span>2005;<span class="ref-vol">134A</span>:84–7.</span> [<a href="/pubmed/15712198" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15712198</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.echevarria.2016.44">Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP. X-chromosome inactivation in female patients with Fabry disease. <span><span class="ref-journal">Clin Genet. </span>2016;<span class="ref-vol">89</span>:44–54.</span> [<a href="/pubmed/25974833" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25974833</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.eng.2007.184">Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. <span><span class="ref-journal">J Inherit Metab Dis. </span>2007;<span class="ref-vol">30</span>:184–92.</span> [<a href="/pubmed/17347915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17347915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.eng.2006.539">Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. <span><span class="ref-journal">Genet Med. </span>2006;<span class="ref-vol">8</span>:539–48.</span> [<a href="/pubmed/16980809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16980809</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.eng.2001.9">Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. <span><span class="ref-journal">N Engl J Med. </span>2001;<span class="ref-vol">345</span>:9–16.</span> [<a href="/pubmed/11439963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11439963</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.fan.1999.112">Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. <span><span class="ref-journal">Nat Med. </span>1999;<span class="ref-vol">5</span>:112–5.</span> [<a href="/pubmed/9883849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9883849</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.ferreira.2015.248">Ferreira S, Ortiz A, Germain DP, Viana-Baptista M, Caldeira-Gomes A, Camprecios M, Fenollar-Cort&#x000e9;s M, Gallegos-Villalobos &#x000c1;, Garcia D, Garc&#x000ed;a-Robles JA, Egido J, Guti&#x000e9;rrez-Rivas E, Herrero JA, Mas S, Oancea R, P&#x000e9;res P, Salazar-Mart&#x000ed;n LM, Solera-Garcia J, Alves H, Garman SC, Oliveira JP. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. <span><span class="ref-journal">Mol Genet Metab. </span>2015;<span class="ref-vol">114</span>:248–58.</span> [<a href="/pmc/articles/PMC4423738/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4423738</span></a>] [<a href="/pubmed/25468652" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25468652</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.froissart.2003.307">Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. <span><span class="ref-journal">Mol Genet Metab. </span>2003;<span class="ref-vol">80</span>:307–14.</span> [<a href="/pubmed/14680977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14680977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.frustaci.2001.25">Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, Eng CM, Desnick RJ. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. <span><span class="ref-journal">N Engl J Med. </span>2001;<span class="ref-vol">345</span>:25–32.</span> [<a href="/pubmed/11439944" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11439944</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.gal.2011.509">Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. <span><span class="ref-journal">J Inherit Metab Dis. </span>2011;<span class="ref-vol">34</span>:509–14.</span> [<a href="/pmc/articles/PMC3063537/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3063537</span></a>] [<a href="/pubmed/21229318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21229318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.galanos.2002.575">Galanos J, Nicholls K, Grigg L, Kiers L, Crawford A, Becker G. Clinical features of Fabry's disease in Australian patients. <span><span class="ref-journal">Intern Med J. </span>2002;<span class="ref-vol">32</span>:575–84.</span> [<a href="/pubmed/12512750" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12512750</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.germain.2015.353">Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE, Packman S, Scott CR, Waldek S, Warnock DG, Weinreb NJ, Wilcox WR. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. <span><span class="ref-journal">J Med Genet. </span>2015;<span class="ref-vol">52</span>:353–8.</span> [<a href="/pmc/articles/PMC4413801/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4413801</span></a>] [<a href="/pubmed/25795794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25795794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.germain.2013.958">Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, Beitner-Johnson D, Benistan K, Cabrera G, Charrow J, Kantola I, Linhart A, Nicholls K, Niemann M, Scott CR, Sims K, Waldek S, Warnock DG, Strotmann J. Fabry Registry. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-&#x003b2;: data from the Fabry Registry. <span><span class="ref-journal">Genet Med. </span>2013;<span class="ref-vol">15</span>:958–65.</span> [<a href="/pubmed/23703683" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23703683</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.ginsberg.2006.57">Ginsberg L, Manara R, Valentine AR, Kendall B, Burlina AP. Magnetic resonance imaging changes in Fabry disease. <span><span class="ref-journal">Acta Paediatr Suppl. </span>2006;<span class="ref-vol">95</span>:57–62.</span> [<a href="/pubmed/16720467" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16720467</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.gokeralpan.2016.95">Goker-Alpan O, Gambello MJ, Maegawa GH, Nedd KJ, Gruskin DJ, Blankstein L, Weinreb NJ. Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry disease. <span><span class="ref-journal">JIMD Rep. </span>2016;<span class="ref-vol">25</span>:95–106.</span> [<a href="/pmc/articles/PMC5059194/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5059194</span></a>] [<a href="/pubmed/26303609" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26303609</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.gupta.2005.261">Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. <span><span class="ref-journal">Medicine (Baltimore). </span>2005;<span class="ref-vol">84</span>:261–8.</span> [<a href="/pubmed/16148726" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16148726</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.hegemann.2006.654">Hegemann S, Hajioff D, Conti G, Beck M, Sunder-Plassmann G, Widmer U, Mehta A, Keilmann A. Hearing loss in Fabry disease: data from the Fabry Outcome Survey. <span><span class="ref-journal">Eur J Clin Invest. </span>2006;<span class="ref-vol">36</span>:654–62.</span> [<a href="/pubmed/16919049" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16919049</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.hoffmann.2007.1447">Hoffmann B, Schwarz M, Mehta A, Keshav S., Fabry Outcome Survey European Investigators.  Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2007;<span class="ref-vol">5</span>:1447–53.</span> [<a href="/pubmed/17919989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17919989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.hsu.2014.96">Hsu TR, Sung SH, Chang FP, Yang CF, Liu HC, Lin HY, Huang CK, Gao HJ, Huang YH, Liao HC, Lee PC, Yang AH, Chiang CC, Lin CY. Yu WC1, Niu DM. Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4&#x02009;+&#x02009;919G&#x02009;&#x0003e;&#x02009;A). <span><span class="ref-journal">Orphanet J Rare Dis. </span>2014;<span class="ref-vol">9</span>:96.</span> [<a href="/pmc/articles/PMC4100491/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4100491</span></a>] [<a href="/pubmed/24980630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24980630</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.hughes.2008.153">Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. <span><span class="ref-journal">Heart. </span>2008 Feb;<span class="ref-vol">94</span>(2):153–8.</span> [<a href="/pubmed/17483124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17483124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.ichinose.2005.228">Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y. Significance of screening for Fabry disease among male dialysis patients. <span><span class="ref-journal">Clin Exp Nephrol. </span>2005;<span class="ref-vol">9</span>:228–32.</span> [<a href="/pubmed/16189631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16189631</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.ishii.2004.250">Ishii S, Yoshioka H, Mannen K, Kulkarni AB, Fan JQ. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. <span><span class="ref-journal">Biochim Biophys Acta. </span>2004;<span class="ref-vol">1690</span>:250–7.</span> [<a href="/pubmed/15511632" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15511632</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.kampmann.2005.15">Kampmann C, Baehner FA, Whybra C, Bajbouj M, Baron K, Knuf M, Wiethoff CM, Tr&#x000fc;bel H, Beck M. The right ventricle in Fabry disease. <span><span class="ref-journal">Acta Paediatr Suppl. </span>2005;<span class="ref-vol">94</span>:15–8.</span> [<a href="/pubmed/15895706" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15895706</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.kleinert.2006.782">Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, Beck M, Ramaswami U, Linhart A, Gal A, Houge G, Widmer U, Mehta A, Sunder-Plassmann G. Prevalence of uncontrolled hypertension in patients with Fabry disease. <span><span class="ref-journal">Am J Hypertens. </span>2006;<span class="ref-vol">19</span>:782–7.</span> [<a href="/pubmed/16876675" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16876675</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.kornreich.1990.9319">Kornreich R, Bishop DF, Desnick RJ. Alpha-galactosidase A gene rearrangements causing Fabry disease. Identification of short direct repeats at breakpoints in an Alu-rich gene. <span><span class="ref-journal">J Biol Chem. </span>1990;<span class="ref-vol">265</span>:9319–26.</span> [<a href="/pubmed/2160973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2160973</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.laney.2013.555">Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J, O'Rourke E, Sims K, Walter G. Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors. <span><span class="ref-journal">J Genet Couns. </span>2013;<span class="ref-vol">22</span>:555–64.</span> [<a href="/pubmed/23860966" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23860966</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.lenders.2015.1009">Lenders M, Karabul N, Duning T, Schmitz B, Schelleckes M, Mesters R, Hense HW, Beck M, Brand SM, Brand E. Thromboembolic events in Fabry disease and the impact of factor V Leiden. <span><span class="ref-journal">Neurology. </span>2015;<span class="ref-vol">84</span>:1009–16.</span> [<a href="/pubmed/25663229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25663229</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.lidove.2012.571">Lidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, Maillot F, Serratrice C, Masseau A, Ch&#x000e9;rin P, Cabane J, Noel E., FIMeD investigators.  Fabry disease 'The New Great Imposter': results of the French Observatoire in Internal Medicine Departments (FIMeD). <span><span class="ref-journal">Clin Genet. </span>2012;<span class="ref-vol">81</span>:571–7.</span> [<a href="/pubmed/21623772" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21623772</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.lidove.2006.1053">Lidove O, Ramaswami U, Jaussaud R, Barbey F, Maisonobe T, Caillaud C, Beck M, Sunder-Plassmann G, Linhart A, Mehta A. Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey. <span><span class="ref-journal">Int J Clin Pract. </span>2006;<span class="ref-vol">60</span>:1053–9.</span> [<a href="/pubmed/16939546" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16939546</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.lin.2009.450">Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, Lin SJ, Chen CH, Chiang CC, Ho HJ, Lee PC, Kao CH, Cheng KH, Hsueh C, Niu DM. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2009;<span class="ref-vol">2</span>:450–6.</span> [<a href="/pubmed/20031620" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20031620</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.linhart.2007.1228">Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, Elliott PM. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. <span><span class="ref-journal">Eur Heart J. </span>2007;<span class="ref-vol">28</span>:1228–35.</span> [<a href="/pubmed/17483538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17483538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.linthorst.2005.201">Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. <span><span class="ref-journal">Clin Chim Acta. </span>2005;<span class="ref-vol">353</span>:201–3.</span> [<a href="/pubmed/15698608" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15698608</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.liu.2015.107">Liu HC, Perrin A, Hsu TR, Yang CF, Lin HY, Yu WC, Niu DM. Age at first cardiac symptoms in Fabry disease: association with a Chinese hotspot Fabry mutation (IVS4+919G&#x0003e;A), classical Fabry mutations, and sex in a Taiwanese population from the Fabry Outcome Survey (FOS). <span><span class="ref-journal">JIMD Rep. </span>2015;<span class="ref-vol">22</span>:107–13.</span> [<a href="/pmc/articles/PMC4486271/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4486271</span></a>] [<a href="/pubmed/25762495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25762495</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.l_hle.2015.1454">L&#x000f6;hle M, Hughes D, Milligan A, Richfield L, Reichmann H, Mehta A, Schapira AH. Clinical prodromes of neurodegeneration in Anderson-Fabry disease. <span><span class="ref-journal">Neurology. </span>2015;<span class="ref-vol">84</span>:1454–64.</span> [<a href="/pmc/articles/PMC4390387/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4390387</span></a>] [<a href="/pubmed/25762709" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25762709</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.lubanda.2009.256">Lubanda JC, Anijalg E, Bzd&#x000fa;ch V, Thurberg BL, B&#x000e9;nichou B, Tylki-Szymanska A. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. <span><span class="ref-journal">Genet Med. </span>2009;<span class="ref-vol">11</span>:256–64.</span> [<a href="/pubmed/19265719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19265719</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.lukas.2016.43">Lukas J, Scalia S, Eichler S, Pockrandt AM, Dehn N, Cozma C, Giese AK, Rolfs A. Functional and Clinical Consequences of Novel &#x003b1;-Galactosidase A Mutations in Fabry Disease. <span><span class="ref-journal">Hum Mutat. </span>2016;<span class="ref-vol">37</span>:43–51.</span> [<a href="/pubmed/26415523" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26415523</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.macdermot.2001.769">MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. <span><span class="ref-journal">J Med Genet. </span>2001;<span class="ref-vol">38</span>:769–75.</span> [<a href="/pmc/articles/PMC1734754/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1734754</span></a>] [<a href="/pubmed/11732485" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11732485</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.magage.2007.790">Magage S, Lubanda JC, Susa Z, Bultas J, Karetova D, Dobrovolny R, Hrebicek M, Germain DP, Linhart A. Natural history of the respiratory involvement in Anderson-Fabry disease. <span><span class="ref-journal">J Inherit Metab Dis. </span>2007;<span class="ref-vol">30</span>:790–9.</span> [<a href="/pubmed/17619837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17619837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.martinez.2007.365">Martinez P, Aggio M, Rozenfeld P. High incidence of autoantibodies in Fabry disease patients. <span><span class="ref-journal">J Inherit Metab Dis. </span>2007;<span class="ref-vol">30</span>:365–9.</span> [<a href="/pubmed/17458709" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17458709</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.mechtler.2012.335">Mechtler TP, Stary S, Metz TF, De Jes&#x000fa;s VR, Greber-Platzer S, Pollak A, Herkner KR, Streubel B, Kasper DC. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. <span><span class="ref-journal">Lancet. </span>2012;<span class="ref-vol">379</span>:335–41.</span> [<a href="/pubmed/22133539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22133539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.mehta.2009.548">Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G, Investigators FOS. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. <span><span class="ref-journal">J Med Genet. </span>2009;<span class="ref-vol">46</span>:548–52.</span> [<a href="/pubmed/19473999" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19473999</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.mehta.2004.236">Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. <span><span class="ref-journal">Eur J Clin Invest. </span>2004;<span class="ref-vol">34</span>:236–42.</span> [<a href="/pubmed/15025684" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15025684</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.meikle.1999.249">Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. <span><span class="ref-journal">JAMA. </span>1999;<span class="ref-vol">281</span>:249–54.</span> [<a href="/pubmed/9918480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9918480</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.moon.2003.2151">Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. <span><span class="ref-journal">Eur Heart J. </span>2003;<span class="ref-vol">24</span>:2151–5.</span> [<a href="/pubmed/14643276" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14643276</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.nakao.2003.801">Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. <span><span class="ref-journal">Kidney Int. </span>2003;<span class="ref-vol">64</span>:801–7.</span> [<a href="/pubmed/12911529" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12911529</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.nguyen.2005.164">Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. <span><span class="ref-journal">Clin Experiment Ophthalmol. </span>2005;<span class="ref-vol">33</span>:164–8.</span> [<a href="/pubmed/15807825" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15807825</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.niemann.2014.8">Niemann M, Rolfs A, St&#x000f6;rk S, Bijnens B, Breunig F, Beer M, Ertl G, Wanner C, Weidemann F. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2014;<span class="ref-vol">7</span>:8–16.</span> [<a href="/pubmed/24395922" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24395922</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.odler.2017.942">Odler B, Cseh &#x000c1;, Constantin T, Fekete G, Losonczy G, Tam&#x000e1;si L, Benke K, Szilveszter B, M&#x000fc;ller V. Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients. <span><span class="ref-journal">Clin Respir J. </span>2017;<span class="ref-vol">11</span>:942–50.</span> [<a href="/pubmed/26763180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26763180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.orteu.2007.331">Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, Ramaswami U, Parini R, Sunder-Plassman G, Beck M, Mehta AB. Fabry disease and the skin: data from FOS, the Fabry outcome survey. <span><span class="ref-journal">Br J Dermatol. </span>2007;<span class="ref-vol">157</span>:331–7.</span> [<a href="/pubmed/17573884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17573884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.ortiz.2016.495">Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart A, Maruti SS, Mauer M, Oliveira JP, Patel MR, Politei J, Waldek S, Wanner C, Yoo HW, Warnock DG. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase &#x003b2;: data from the Fabry Registry. <span><span class="ref-journal">J Med Genet. </span>2016;<span class="ref-vol">53</span>:495–502.</span> [<a href="/pmc/articles/PMC4941144/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4941144</span></a>] [<a href="/pubmed/26993266" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26993266</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.pan.2016.e0161330">Pan X, Ouyang Y, Wang Z, Ren H, Shen P, Wang W, Xu Y, Ni L, Yu X, Chen X, Zhang W, Yang L, Li X, Xu J, Chen N. Genotype: A Crucial but Not Unique Factor Affecting the Clinical Phenotypes in Fabry Disease. <span><span class="ref-journal">PLoS One. </span>2016;<span class="ref-vol">11</span>:e0161330.</span> [<a href="/pmc/articles/PMC4999276/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4999276</span></a>] [<a href="/pubmed/27560961" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27560961</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.patel.2015.961">Patel V, O'Mahony C, Hughes D, Rahman MS, Coats C, Murphy E, Lachmann R, Mehta A, Elliott PM. Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease. <span><span class="ref-journal">Heart. </span>2015;<span class="ref-vol">101</span>:961–6.</span> [<a href="/pubmed/25655062" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25655062</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.pieroni.2006.1663">Pieroni M, Chimenti C, De Cobelli F, Morgante E, Del Maschio A, Gaudio C, Russo MA, Frustaci A. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. <span><span class="ref-journal">J Am Coll Cardiol. </span>2006;<span class="ref-vol">47</span>:1663–71.</span> [<a href="/pubmed/16631007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16631007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.pisani.2013.41">Pisani A, Spinelli L, Visciano B, Capuano I, Sabbatini M, Riccio E, Messalli G, Imbriaco M. Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. <span><span class="ref-journal">JIMD Rep. </span>2013;<span class="ref-vol">9</span>:41–8.</span> [<a href="/pmc/articles/PMC3565648/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3565648</span></a>] [<a href="/pubmed/23430546" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430546</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.pitz.2015.e0120814">Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S, Beck M, Gal A. Ocular signs correlate well with disease severity and genotype in Fabry disease. <span><span class="ref-journal">PLoS One. </span>2015;<span class="ref-vol">10</span>:e0120814.</span> [<a href="/pmc/articles/PMC4363518/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4363518</span></a>] [<a href="/pubmed/25781336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25781336</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.politei.2006.103">Politei JM, Capizzano AA. Magnetic resonance image findings in 5 young patients with Fabry disease. <span><span class="ref-journal">Neurologist. </span>2006;<span class="ref-vol">12</span>:103–5.</span> [<a href="/pubmed/16534447" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16534447</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.ramaswami.2006.86">Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. <span><span class="ref-journal">Acta Paediatr. </span>2006;<span class="ref-vol">95</span>:86–92.</span> [<a href="/pubmed/16498740" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16498740</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.ries.2003.413">Ries M, Mengel E, Kutschke G, Kim KS, Birklein F, Krummenauer F, Beck M. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. <span><span class="ref-journal">J Inherit Metab Dis. </span>2003;<span class="ref-vol">26</span>:413–4.</span> [<a href="/pubmed/12971431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12971431</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.rolfs.2005.1794">Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, Lohr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. <span><span class="ref-journal">Lancet. </span>2005;<span class="ref-vol">366</span>:1794–6.</span> [<a href="/pubmed/16298216" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16298216</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.rolfs.2013.340">Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, B&#x000f6;ttcher T, Heuschmann PU, Tatlisumak T, Tanislav C, Jungehulsing GJ, Giese AK, Putaala J, Huber R, Bodechtel U, Lichy C, Enzinger C, Schmidt R, Hennerici MG, Kaps M, Kessler C, Lackner K, Paschke E, Meyer W, Mascher H, Riess O, Kolodny E, Norrving B. Stroke in Young Fabry Patients (sifap) Investigators. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients Study. <span><span class="ref-journal">Stroke. </span>2013;<span class="ref-vol">44</span>:340–9.</span> [<a href="/pubmed/23306324" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23306324</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.rombach.2013.29">Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for Fabry disease. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2013;<span class="ref-vol">8</span>:29.</span> [<a href="/pmc/articles/PMC3598841/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3598841</span></a>] [<a href="/pubmed/23421808" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23421808</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.sachdev.2002.1407">Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. <span><span class="ref-journal">Circulation. </span>2002;<span class="ref-vol">105</span>:1407–11.</span> [<a href="/pubmed/11914245" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11914245</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.sadek.2004.199">Sadek J, Shellhaas R, Camfield CS, Camfield PR, Burley J. Psychiatric findings in four female carriers of Fabry disease. <span><span class="ref-journal">Psychiatr Genet. </span>2004;<span class="ref-vol">14</span>:199–201.</span> [<a href="/pubmed/15564893" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15564893</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.sado.2013.392">Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. <span><span class="ref-journal">Circ Cardiovasc Imaging. </span>2013 May 1;<span class="ref-vol">6</span>(3):392–8.</span> [<a href="/pubmed/23564562" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23564562</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.schaefer.2005.87">Schaefer E, Mehta A, Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. <span><span class="ref-journal">Acta Paediatr Suppl. </span>2005;<span class="ref-vol">94</span>:87–92.</span> [<a href="/pubmed/15895718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15895718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.sch_fer.2005.412">Sch&#x000e4;fer E, Baron K, Widmer U, Deegan P, Neumann HP, Sunder-Plassmann G, Johansson JO, Whybra C, Ries M, Pastores GM, Mehta A, Beck M, Gal A. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">25</span>:412.</span> [<a href="/pubmed/15776423" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15776423</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.schiffmann.2007.1576">Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO, Ries M. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. <span><span class="ref-journal">J Am Soc Nephrol. </span>2007;<span class="ref-vol">18</span>:1576–83.</span> [<a href="/pmc/articles/PMC1978101/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1978101</span></a>] [<a href="/pubmed/17409308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17409308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.schiffmann.2001.2743">Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. <span><span class="ref-journal">JAMA. </span>2001;<span class="ref-vol">285</span>:2743–9.</span> [<a href="/pubmed/11386930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11386930</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.schiffmann.2015.1129">Schiffmann R, Swift C, Wang X, Blankenship D, Ries M. A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease. <span><span class="ref-journal">J Inherit Metab Dis. </span>2015;<span class="ref-vol">38</span>:1129–36.</span> [<a href="/pubmed/25900714" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25900714</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.shah.2005.842">Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, Mehta AB, Elliott PM. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. <span><span class="ref-journal">Am J Cardiol. </span>2005;<span class="ref-vol">96</span>:842–6.</span> [<a href="/pubmed/16169374" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16169374</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.sims.2009.788">Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. <span><span class="ref-journal">Stroke. </span>2009;<span class="ref-vol">40</span>:788–94.</span> [<a href="/pubmed/19150871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19150871</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.sirrs.2014.499">Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S, West ML., CFDI investigators.  Outcomes of patients treated through the Canadian Fabry disease initiative. <span><span class="ref-journal">Mol Genet Metab. </span>2014;<span class="ref-vol">111</span>:499–506.</span> [<a href="/pubmed/24534763" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24534763</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.smid.2011.69">Smid BE, Rombach SM, Aerts JM, Kuiper S, Mirzaian M, Overkleeft HS, Poorthuis BJ, Hollak CE, Groener JE, Linthorst GE. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2011;<span class="ref-vol">6</span>:69.</span> [<a href="/pmc/articles/PMC3219561/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3219561</span></a>] [<a href="/pubmed/22041095" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22041095</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.smid.2014.400">Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, Timmermans J, Weidemann F, West ML, Biegstraaten M, Lekanne Deprez RH, Florquin S, Postema PG, Tomberli B, van der Wal AC, van den Bergh Weerman MA, Hollak CE. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. <span><span class="ref-journal">Int J Cardiol. </span>2014;<span class="ref-vol">177</span>:400–8.</span> [<a href="/pubmed/25442977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25442977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.sodi.2007.210">Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey. <span><span class="ref-journal">Br J Ophthalmol. </span>2007;<span class="ref-vol">91</span>:210–4.</span> [<a href="/pmc/articles/PMC1857640/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1857640</span></a>] [<a href="/pubmed/16973664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16973664</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.spada.2006.31">Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset fabry disease revealed by newborn screening. <span><span class="ref-journal">Am J Hum Genet. </span>2006;<span class="ref-vol">79</span>:31–40.</span> [<a href="/pmc/articles/PMC1474133/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1474133</span></a>] [<a href="/pubmed/16773563" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16773563</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.tahir.2007.2609">Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. <span><span class="ref-journal">J Am Soc Nephrol. </span>2007;<span class="ref-vol">18</span>:2609–17.</span> [<a href="/pubmed/17656478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17656478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.tanaka.2005.281">Tanaka M, Ohashi T, Kobayashi M, Eto Y, Miyamura N, Nishida K, Araki E, Itoh K, Matsushita K, Hara M, Kuwahara K, Nakano T, Yasumoto N, Nonoguchi H, Tomita K. Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. <span><span class="ref-journal">Clin Nephrol. </span>2005;<span class="ref-vol">64</span>:281–7.</span> [<a href="/pubmed/16240899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16240899</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.terryn.2013.101">Terryn W, Vanholder R, Hemelsoet D, Leroy BP, Van Biesen W, De Schoenmakere G, Wuyts B, Claes K, De Backer J, De Paepe G, Fogo A, Praet M, Poppe B. Questioning the Pathogenic Role of the GLA p.Ala143Thr "Mutation" in Fabry Disease: Implications for Screening Studies and ERT. <span><span class="ref-journal">JIMD Rep. </span>2013;<span class="ref-vol">8</span>:101–8.</span> [<a href="/pmc/articles/PMC3565658/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3565658</span></a>] [<a href="/pubmed/23430526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430526</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.tsuboi.2012.779">Tsuboi K, Yamamoto H. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). <span><span class="ref-journal">Genet Med. </span>2012;<span class="ref-vol">14</span>:779–86.</span> [<a href="/pmc/articles/PMC3908501/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3908501</span></a>] [<a href="/pubmed/22498845" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22498845</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.waldek.2014.72">Waldek S, Feriozzi S. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy? <span><span class="ref-journal">BMC Nephrol. </span>2014;<span class="ref-vol">15</span>:72.</span> [<a href="/pmc/articles/PMC4029839/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4029839</span></a>] [<a href="/pubmed/24886109" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24886109</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.waldek.2009.790">Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. <span><span class="ref-journal">Genet Med. </span>2009;<span class="ref-vol">11</span>:790–6.</span> [<a href="/pubmed/19745746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19745746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.warnock.2015.860">Warnock DG, Thomas CP, Vujkovac B, Campbell RC, Charrow J, Laney DA, Jackson LL, Wilcox WR, Wanner C. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy. <span><span class="ref-journal">J Med Genet. </span>2015;<span class="ref-vol">52</span>:860–6.</span> [<a href="/pmc/articles/PMC4717450/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4717450</span></a>] [<a href="/pubmed/26490103" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26490103</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.weidemann.2005.1221">Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. <span><span class="ref-journal">Eur Heart J. </span>2005;<span class="ref-vol">26</span>:1221–7.</span> [<a href="/pubmed/15728649" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15728649</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.weidemann.2013.331">Weidemann F, Niemann M, St&#x000f6;rk S, Breunig F, Beer M, Sommer C, Herrmann S, Ertl G, Wanner C. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. <span><span class="ref-journal">J Intern Med. </span>2013;<span class="ref-vol">274</span>:331–41.</span> [<a href="/pmc/articles/PMC4282332/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4282332</span></a>] [<a href="/pubmed/23586858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23586858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.whitley.1983.2177">Whitley CB, Tsai MY, Heger JJ, Prystowsky EN, Zipes DP. Amiodarone phenocopy of Fabry's keratopathy. <span><span class="ref-journal">JAMA. </span>1983;<span class="ref-vol">249</span>:2177–8.</span> [<a href="/pubmed/6300478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6300478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.whybra.2001.715">Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Bruhl K, Gal A, Bunge S, Beck M. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. <span><span class="ref-journal">J Inherit Metab Dis. </span>2001;<span class="ref-vol">24</span>:715–24.</span> [<a href="/pubmed/11804208" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11804208</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.wijburg.2015.e0124987">Wijburg FA, B&#x000e9;nichou B, Bichet DG, Clarke LA, Dostalova G, Fainboim A, Fellgiebel A, Forcelini C. An Haack K, Hopkin RJ, Mauer M, Najafian B, Scott CR, Shankar SP, Thurberg BL, T&#x000f8;ndel C, Tylki-Szyma&#x00144;ska A, Ramaswami U. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial. <span><span class="ref-journal">PLoS One. </span>2015;<span class="ref-vol">10</span>:e0124987.</span> [<a href="/pmc/articles/PMC4425695/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4425695</span></a>] [<a href="/pubmed/25955246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25955246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.wilcox.2012.443">Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, Beitner-Johnson D, Cizmarik M, Cole JA, Kingma W, Warnock DG. Anti-&#x003b1;-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">105</span>:443–9.</span> [<a href="/pubmed/22227322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22227322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.wilcox.2008.112">Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP. Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. <span><span class="ref-journal">Mol Genet Metab. </span>2008;<span class="ref-vol">93</span>:112–28.</span> [<a href="/pubmed/18037317" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18037317</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.wozniak.2010.78">Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, Grace ME, Nazarenko I, Dobrovolny R, McDade E, Desnick RJ. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. <span><span class="ref-journal">Stroke. </span>2010;<span class="ref-vol">41</span>:78–81.</span> [<a href="/pmc/articles/PMC3564050/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3564050</span></a>] [<a href="/pubmed/20007919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20007919</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.yasuda.2003.162">Yasuda M, Shabbeer J, Osawa M, Desnick RJ. Fabry disease: novel alpha-galactosidase A 3'-terminal mutations result in multiple transcripts due to aberrant 3'-end formation. <span><span class="ref-journal">Am J Hum Genet. </span>2003;<span class="ref-vol">73</span>:162–73.</span> [<a href="/pmc/articles/PMC1180577/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1180577</span></a>] [<a href="/pubmed/12796853" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12796853</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.zampetti.2012.712">Zampetti A, Orteu CH, Antuzzi D, Bongiorno MR, Manco S, Gnarra M, Morrone A, Cardinali G, Kovacs D, Aspite N, Linder D, Parini R, Feliciani C., Interdisciplinary Study Group on Fabry Disease (ISGF).  Angiokeratoma: decision-making aid for the diagnosis of Fabry disease. <span><span class="ref-journal">Br J Dermatol. </span>2012;<span class="ref-vol">166</span>:712–20.</span> [<a href="/pubmed/22452439" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22452439</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.ziegler.2002.935">Ziegler RJ, Li C, Cherry M, Zhu Y, Hempel D, van Rooijen N, Ioannou YA, Desnick RJ, Goldberg MA, Yew NS, Cheng SH. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. <span><span class="ref-journal">Hum Gene Ther. </span>2002;<span class="ref-vol">13</span>:935–45.</span> [<a href="/pubmed/12031126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12031126</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.ziegler.2004.231">Ziegler RJ, Lonning SM, Armentano D, Li C, Souza DW, Cherry M, Ford C, Barbon CM, Desnick RJ, Gao G, Wilson JM, Peluso R, Godwin S, Carter BJ, Gregory RJ, Wadsworth SC, Cheng SH. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. <span><span class="ref-journal">Mol Ther. </span>2004;<span class="ref-vol">9</span>:231–40.</span> [<a href="/pubmed/14759807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14759807</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.ziegler.1999.1667">Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette P, Romanczuk H, Ioannou YA, Zeidner KM, Desnick RJ, Cheng SH. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. <span><span class="ref-journal">Hum Gene Ther. </span>1999;<span class="ref-vol">10</span>:1667–82.</span> [<a href="/pubmed/10428212" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10428212</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fabry.REF.zizzo.2013.576">Zizzo C, Colomba P, Albeggiani G, Gallizzi R, Iemolo F, Nuzzo D, Vasto S, Caruso C, Duro G. Misdiagnosis of familial Mediterranean fever in patients with Anderson-Fabry disease. <span><span class="ref-journal">Clin Genet. </span>2013;<span class="ref-vol">83</span>:576–81.</span> [<a href="/pubmed/22905681" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22905681</span></a>]</div></li></ul></div></div><div id="fabry.Chapter_Notes"><h2 id="_fabry_Chapter_Notes_">Chapter Notes</h2><div id="fabry.Author_History"><h3>Author History</h3><p>Kenneth H Astrin, PhD; Mount Sinai School of Medicine (2001-2008) <br />Robert J Desnick, PhD, MD; Mount Sinai School of Medicine (2001-2008) <br />Derralynn A Hughes, MA, DPhil, FRCP, FRCPath (2008-present) <br />Atul Mehta, MA, MD, FRCP, FRCPath (2008-present)</p></div><div id="fabry.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>5 January 2017 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 October 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 March 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 February 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 August 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 January 2004 (rd) Revision: Management - ERT</div></li><li class="half_rhythm"><div>5 August 2002 (me) Review posted live</div></li><li class="half_rhythm"><div>17 September 2001 (rd) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1292</span><span class="label">PMID: <a href="/pubmed/20301469" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301469</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/xl-nystag/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fsh/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1292&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1292/?report=reader">PubReader</a></li><li><a href="/books/NBK1292/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1292" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1292" style="display:none" title="Cite this Page"><div class="bk_tt">Mehta A, Hughes DA. Fabry Disease. 2002 Aug 5 [Updated 2017 Jan 5]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1292/pdf/Bookshelf_NBK1292.pdf">PDF version of this page</a> (545K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#fabry.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#fabry.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#fabry.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#fabry.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#fabry.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#fabry.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#fabry.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#fabry.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#fabry.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#fabry.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#fabry.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#fabry.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2717[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GLA</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1472716" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1472716" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1472716" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1472716" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301298" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Darras BT, Urion DK, Ghosh PS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22876375" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dent Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dent Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lieske JC, Milliner DS, Beara-Lasic L, Harris P, Cogal A, Abrash E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301451" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mucopolysaccharidosis Type II</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mucopolysaccharidosis Type II<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Scarpa M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301386" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alport Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alport Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kashtan CE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301469" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301469" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0429f275f66d18aaf25bbb">Fabry Disease - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Fabry Disease - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:33:06-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8AA828E04214110000000003A60178&amp;ncbi_session=CE8AA828E0429F21_0934SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1292%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1292&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1292/&amp;ncbi_pagename=Fabry Disease - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8AA828E0429F21_0934SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>